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ABSTRACT 
NOVEL STRATEGIES TO MODULATE SYNAPTIC COMMUNICATION AND 
INVESTIGATE THE ROLE OF HDAC6 IN ALZHEIMER’S DISEASE 
 
MAY 2014 
 
KATHRYNE A. MEDEIROS 
 
B.S., BRIDGEWATER STATE UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor James J. Chambers 
 
 
 Neuronal communication is mediated by chemical signaling at the synapse.  The 
underlying molecular mechanisms of learning and memory are poorly understood.  Very 
few tools are available to study how memories are formed in the mammalian brain.  This 
dissertation focuses on developing novel strategies to study neural activity.  Here we 
develop and use a chemical-genetic approach to enable target-specific photocontrol of 
inhibitory synaptic neurotransmission of GABAA receptor subtypes.  The tools developed 
here selectively photocontrolled GABAA receptor subtypes.  This enabled the 
investigation of the functional role these receptor subtypes have in inhibitory synaptic 
neurotransmission.  This dissertation also focuses on identifying the role of HDAC6 in 
Alzheimer’s disease.  Increased expression of HDAC6 was identified as an underlying 
molecular factor that led to pathological tau accumulation and early changes that 
correlate with synaptic dysfunction, hallmarks of Alzheimer’s disease. 
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 1 
1 CHAPTER 1 
INTRODUCTION 
1.1  Neurons 
 Neurons are post-mitotic polarized cells in the brain specialized for 
communication via chemical signaling.  The main morphological characteristics of a 
neuron are a cell body with a single axon and multiple dendrites extending from the cell 
body (Figure 1.1A).  Axon morphology and function is dependent on microtubules 
(Conde and Caceres, 2009).  Dendrites have branched processes of micron-sized 
protrusions called dendritic spines (Perez et al., 2009; Penzes et al., 2011; Shirao and 
Gonzalez-Billault, 2013; Jaworski et al., 2009).  The morphology and function of dendritic 
spines is dependent on cytoskeletal actin filaments (Sala and Segal, 2014; Hotulainen 
and Hoogenraad, 2010; Dent et al., 2011; Gu and Zheng, 2009).  Both microtubules and 
actin dynamics are critical for the development of neuronal polarity and synaptic 
communication (Conde and Caceres, 2009).  The polymerization dynamics of actin and 
microtubules play an important role in neuron morphology, communication, and survival.   
 The axon contains a parallel bundle of microtubules with the plus ends oriented 
towards the cell periphery and the minus end oriented towards the cell body (Dixit et al., 
2008; Conde and Caceres, 2009; Shirao and Gonzalez-Billault, 2013).  Microtubules are 
integral structural components of the cell composed of α and β tubulin heterodimers that 
are necessary for cytoskeleton support serving as a track for directional axonal transport 
of cargos such as proteins, vesicles, and organelles (Buee et al., 2000; Conde and 
Caceres, 2009).  Neuronal survival depends on highly regulated functional axonal 
transport of cargos to and from the cell body to distal portions of the cell.
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Figure 1.1. Neuron Morphology 
 
A) Cartoon depiction of a healthy polarized neuron illustrating the main features of a 
neuron including axon, soma, presynaptic axon terminal, dendrites, and postsynaptic 
dendritic spines.  
B) Cartoon depiction of morphological characteristics of postsynaptic dendritic spines. 
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 The axon transmits chemical signals via neurotransmitter release at the 
presynaptic terminal.  Dendrites have multiple branched processes of dendritic spines 
that receive these chemical signals at a site called the postsynaptic terminal.  
Communication between the presynaptic terminal and the postsynaptic terminal form a 
specialized site of chemical signaling responsible for neurotransmission as well as 
learning and memory and is called the synapse.  Trafficking of cargo to presynaptic and 
postsynaptic terminals contribute to the development of mature synapses (Niesmann et 
al., 2011).  Changes in size and shape of the dendritic spine correlate with the strength 
of the synaptic connection and the remodeling of the underlying actin cytoskeleton 
(Hotulainen and Hoogenraad, 2010).  Dendritic spines are highly dynamic structures that 
change size and shape at timescales that range from seconds to minutes to hours 
(Hering and Sheng, 2001; Kasai et al., 2010).  Dendritic spines are often categorized by 
morphology into three categories: thin spines, stubby spines, and mushroom spines 
(Figure 1.1B) (Hotulainen and Hoogenraad, 2010; Jaworski et al., 2009; Harris and 
Kater, 1994; Hering and Sheng, 2001).  These classifications of dendritic spine 
morphology are critical for neuronal communication and believed to be snapshots of 
underlying synaptic plasticity (Shirao and Gonzalez-Billault, 2013).   
1.2  Synaptic Plasticity 
 The ability of a neuron to modify communication at the synapse in response to 
changes at the synapse is referred to as synaptic plasticity.  Synaptic plasticity is the 
underlying mechanism of learning and memory.  This change in synaptic strength is 
regulated at the presynaptic terminal by neurotransmitter release and by receptors at the 
postsynaptic terminal.  Homeostasis of neuronal communication is maintained by a 
balance between strengthening synaptic communication by long-term potentiation (LTP) 
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and reducing the strength of synaptic communication by long-term depression (LTD) 
(Figure 1.2).   
 LTP is an increase in synaptic strength and associated with dendritic spine 
enlargement (Kasai et al., 2010; Shepherd and Huganir, 2007; Pontrello et al., 2012; 
Collingridge et al., 2004).  Enlargements of dendritic spines and increased receptor 
trafficking to the postsynaptic sites are associated with LTP.  Changes in the functional 
strength of synapses, the size and shape of dendritic spines, as well as the physical 
connectivity of neural networks all contribute to LTP (Bingol and Sheng, 2011).  LTD is a 
decrease in synaptic strength associated with a reduction in the number and size of 
dendritic spines (Pontrello et al., 2012; Shepherd and Huganir, 2007).  This reduction in 
dendritic spine size and number as well as decreased receptor trafficking are associated 
with LTD.  Altered neuronal communication at the synapse and a decreased number of 
postsynaptic receptors correlate with a reduction in synaptic strength and plasticity 
(Bingol and Sheng, 2011).  Actin polymerization is involved in LTP and actin 
depolymerization is involved in LTD (Matsuzaki et al., 2004; Okamoto et al., 2004; Zhou 
et al., 2004).  Synaptic remodeling and cellular homeostasis requires proper protein 
turnover that is coordinated by protein synthesis and protein degradation (Bingol and 
Sheng, 2011).   
 Impaired LTP and induced LTD are associated with disease and defects in 
learning and memory (Hering and Sheng, 2001; Keifer and Zheng, 2010; Shepherd and 
Huganir, 2007).  Abnormal synaptic communication resulting from changes in dendritic 
spine density and shape has been observed in a number of neurological disorders 
(Penzes et al., 2011).  Defects in protein degradation lead to the accumulation of toxic  
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Figure 1.2. Synaptic Plasticity 
 
Cartoon illustration of mechanisms underlying synaptic plasticity.  During LTP there is an 
increase in synaptic strength and receptors at the synapse where as during LTD there is 
a decrease in synaptic strength and receptors at the synapse. Excitatory 
neurotransmission at the synapse is regulated by glutamate neurotransmitter release 
and two main types of glutamate-gated ion channels: AMPA and NMDA.  Inhibitory 
neurotransmission at the synapse is regulated by γ-aminobutyric acid (GABA) 
neurotransmitter release and ionotropic GABAA receptors.  
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protein aggregates and are associated with neurological diseases.  Reduced protein 
degradation is the result of defective protein clearance.  Defects in the ubiquitin 
proteasome system (UPS), lysosomes, and autophagy have been associated with 
defective protein clearance and neurological disease (Bingol and Sheng, 2011).  Protein 
aggregation, accumulation, and deposition are hallmarks of neurodegenerative diseases 
and are believed to be the result of impaired protein degradation pathways.  Impaired 
synaptic plasticity is the result of degeneration of axons and dendritic spines leading to 
loss of synapses.   
1.3  Excitatory and Inhibitory Neurotransmission 
 Communication at the synapse is mediated by neurotransmitter release from the 
presynaptic terminal and receptor activation at the postsynaptic terminal.  Excitatory 
neurotransmission at the synapse is regulated by glutamate neurotransmitter release 
and two main types of glutamate-gated ion channels: α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors 
(Collingridge et al., 2004; Keifer and Zheng, 2010; Pinheiro and Mulle, 2008; Rao and 
Finkbeiner, 2007).  AMPA receptors are composed of combinations of four subunits 
(GluR1, GluR2, GluR3, GluR4) (Rao and Finkbeiner, 2007; Shepherd and Huganir, 
2007).  NMDA receptors are heterotetramers composed of combinations of NR1 subunit, 
NR2 subunits (NR2A, NR2B, NR2C, NR2D), and NR3 subunits (NR3A, NR3B) (Paoletti 
et al., 2013).  An important scaffolding protein, postsynaptic density protein 95 (PSD-95) 
plays a pivotal role in LTP and LTD (Bhattacharyya et al., 2009; Chen et al., 2011).  
PSD-95 plays a functional role in maintaining molecular organization of excitatory 
dendritic spines.  PSD-95 is the most-abundant scaffolding protein in postsynaptic 
densities, and is one of the most stable proteins in dendritic spines (Chen et al., 2011; 
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Kasai et al., 2010).  Inhibitory neurotransmission at the synapse is regulated by γ-
aminobutyric acid (GABA) neurotransmitter release and ionotropic GABAA receptors 
(D'Hulst et al., 2009).  GABAA receptors are heteropentamers containing the common 
stoichiometry of two subunits of α and two β and an additional subunit of γ or δ (Belelli 
and Lambert, 2005).  Variation of subunit composition of receptors allows for differential 
expression patterns, localization (extrasynaptic vs. synaptic), pharmacology and 
function.  The role that subunit composition, differential expression patterns, 
extrasynaptic and synaptic localization plays in synaptic communication, function and 
dysfunction in neurological diseases has been elusive.   
1.4  Controlling Synaptic Neurotransmission   
 Mammalian cells have ion channels that are activated by ligand binding, voltage, 
and temperature but they are not activated by light (Banghart et al., 2004).  To control 
neural circuits, we can engineer ion channels to be activated or inhibited by light.  
Engineering ion-channels to respond to light enables exploration and manipulation of 
synaptic neurotransmission.  Light is a non-invasive method that enables spatial and 
temporal resolution to control neural activity (Boyden et al., 2005; Fortin et al., 2008; 
Kramer et al., 2005; Kramer et al., 2009; Thompson et al., 2005).  Advances in 
microscopy, optical physics and laser instrumentation allows for a beam of light of a 
certain wavelength to be focused on a subcellular region of a cell, on a single cell, or 
projected diffusely to regulate a network of cells thus activating or inhibiting ion channels 
enabling photocontrol of synaptic neurotransmission that regulates synaptic plasticity 
and behavior using light (Fortin et al., 2008; Kramer et al., 2005; Thompson et al., 2005). 
 Optical methods for controlling synaptic neurotransmission using light include: 
caged neurotransmitters, natural photosensitive proteins, and synthetic small molecule 
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photoswitches (Chambers and Kramer, 2008; Kramer et al., 2005; Thompson et al., 
2005).  These optical light sensitive tools offer precise, non-invasive control of neural 
activity.  Caged neurotransmitters have a photolabile protecting group that renders them 
biologically inactive until the protecting group is removed or ‘uncaged’ upon exposure to 
light releasing the neurotransmitter (Ellis-Davies, 2007; Fortin et al., 2008; Kramer et al., 
2009; Thompson et al., 2005).  Caged neurotransmitters have several caveats: light-
scattering limits the precision of uncaging, the uncaging of neurotransmitter is 
irreversible, prolonged uncaging can lead to receptor desensitization and local depletion 
of the caged neurotransmitter can limit long-term experiments (Fortin et al., 2008; 
Kramer et al., 2009).  Advances in molecular biology led to gene delivery of the natural 
photosensitive protein Channelrhodopsin-2 (ChR2), a light-gated cation channel that 
contains the photoisomerizable molecule retinal to neuronal subtypes (Boyden et al., 
2005; Zhang et al., 2006).  Exposure to light triggers retinal isomerization leading to a 
conformational change in the photosensitive protein, which opens the channel thus 
enabling photocontrol of neurons.  A caveat to natural photosensitive proteins is that the 
gene encoding the photosensitive protein needs to be delivered to the neurons of 
interest and the protein needs to be expressed and trafficked to the plasma membrane.  
Alternatively, photocontrol of neurons can be achieved through synthetic chemistry and 
the use of small molecule photoswitches.   
 Small molecule photoswitches have been used to convert ion channels to light-
sensitive ion channels.  Small molecule photoswitches are photoisomerizable molecules 
in which the conformation of the molecule changes in response to specific wavelengths 
of light.  Azobenzenes as a small molecule photoswitch that have been commonly used 
to develop synthetically-photosensitive ion channels.  Azobenezenes are often the small 
molecule photoswitch of choice because of their biological suitability, low phototoxicity, 
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ease of synthesis, and photochemical stability (Kramer et al., 2009).  Azobenzenes 
photoswitch from an extended trans isomer conformation in response to illumination with 
visible light >460 nm and upon illumination with ultraviolet (UV) light at 380 nm convert 
to a cis bent isomer conformation approximately 7Å shorter than the trans isomer 
conformation (Figure 1.3) (Banghart et al., 2006; Feliciano et al., 2010).  A ligand can 
then be coupled to the small molecule photoswitch to target the photoswitchable ligand 
to a receptor of interest by affinity labeling.  In order to prevent the limitations of using a 
freely diffusible light-sensitive photoswitchable ligand often a molecule that can 
covalently bind the photoswitchable ligand to the receptor of interest is employed.  
Maleimide molecules are commonly used to covalently attach photoswitchable ligands to 
receptors by cysteine-reactivity to residues on the surface of the target protein.  
Specificity can be achieved by engineering a cysteine to a specific location on the 
receptor of interest rather than relying on endogenous cysteines.  Genetic engineering of 
a cysteine to the appropriate location for target photoswitch tethering prevents diffusion 
of photo-tethered ligand and off target effects.  Attachment of the small molecule 
photoswitch to the ion channel of interest enables photocontrol of receptor activity.   
 By employing a photoswitchable tethered ligand (PTL) to photocontrol ion 
channels the activity of a neuron can be modulated by light without diffusion of the PTL 
thus increasing the local concentration of the ligand near the target protein.  This “drugs” 
activity can be turned on and off using specific wavelengths of light to control chemical 
signaling of receptors involved in learning and memory at synapses thus creating a light-
gated ion channel that can be reversibly photocontrolled in response to irradiation with 
ultraviolet or visible light by altering the location of the ligand in relation to the ligand 
binding site (Figure 1.4). This PTL strategy has been used to photocontrol the activity of 
 10 
 
 
Figure 1.3. Azobenzene Photoswitch  
 
Illustration showing azobenzene isoform configuration to extended trans isomer in 
response to irradiation with visible light (>460 nm) and to bent cis isomer in response to 
irradiation with ultraviolet light (360-380 nm).  Figure adapted from (Banghart et al., 
2006).  
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Figure 1.4. Photocontrol of Ion Channels 
 
Cartoon illustration of the photocontrol of ion channels.  Tethered small molecule 
photoswitches enable remote photocontrol of neuron ion channels using specific 
wavelengths of light.  Shown here photocontrol of neuronal firing of synthetic 
photoisomerizable azobenzene-regulated K+ (SPARK) channels.  In green (illumination 
with visible light) spontaneous action potential firing occurs, and in purple (illumination 
with ultraviolet light) action potentials are silenced.  Figure adapted from (Kramer et al., 
2005). 
 
     
 
calcium buffers, caged nucleotides, and even caged pep-
tides that influence intracellular signal transduction path-
ways. The first caged neurotransmitter agonists were
o-nitrobenzyl derivatives of carbamoylcholine, an activa-
tor of acetylcholine receptors that was released in
response to UV light [1,2]. These molecules enabled a
rapid jump in agonist concentration in response to light,
leading to a better understanding of the kinetics of
acetylcholine receptor activation. But it was the devel-
opment of caged glutamate [3] that had a major impact on
neurobiology. Dalva and Katz were the first to use a laser
to locally uncage glutamate in an intact brain slice [4].
Laser photostimulation of presynaptic neurons revealed
that the pattern of connections to visual cortical neurons
changes during development, a finding that would have
been difficult to obtain without local glutamate uncaging.
Unfortunately, however, light scattering limits the spatial
precision of laser uncaging. This problem motivated the
development of caged molecules that could be photo-
lyzed by two-photon illumination, which can pinpoint the
liberation of neurotransmitter to individual neurons and
even individual dendritic spines. MNI-caged glutamate
(4-methoxy-7-nitroindolinyl-caged L-glutamate) has a
favorable two-photon cross-section, and because of this,
it is now the most popular form of caged glutamate (for
review see [5!]). Adding to its usefulness, MNI-caged
glutamate has a very low rate of spontaneous glutamate
liberation in the dark and the free ‘cage’ that is formed as
a byproduct of the photolysis reaction has no apparent
effect on neuronal function.
Two-photon uncaging of MNI-glutamate can trigger
responses that simulate the kinetics and magnitude of
individual synaptic events on single dendritic spines [6!!].
Fortunately, abundant and highly active glutamate trans-
porters rapidly remove the liberated glutamate, minimiz-
ing spillover onto neighboring spines. Uncaging at single
spines is beneficial for several reasons. It allows direct
comparison of spine geometry and postsynaptic respon-
siveness. It allows precise measurement of spatial sum-
mation across neighboring spines. It removes any
ambiguity in attributing plastic changes in synaptic func-
tion to the presynaptic versus the postsynaptic cell.
Highly localized and rapid uncaging of glutamate requires
very bright light and a high concentration of caged
compound (mM range). These requirements present
potential problems of phototoxicity and off-target effects
on other types of receptors. The development of new
types of caged glutamate with an even more favorable
two-photon cross-section may help alleviate these pro-
blems [7,8]. At the same time, investigators are develop-
ing forms of caged glutamate that can be uncaged by
2 Sensory systems
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Figure 1
Photochemical tools for control of neuronal activity. Three categories of tools are illustrated: caged molecules (left), natural photosensitive proteins
(center) and small molecule photoswitches (right). Specific examples are shown below in the green boxes. Abbreviations: DMNB-glu, 4,5-dimethoxy-
2-nitrobenzyl-glutamate [4]; MNI-glu, 4-methoxy-7-nitroindolinyl-caged glutamate [6!!]; ChR2 (channelrhodopsin-2), a cation channel from
Chlamydomonas reinhardtii [22!!]; VChR1 (channelrodhopsin-1), a cation channel from Volvox carteri [38]; NpHR (halorhodopsin), a chloride
transporter from Natronomonas pharaonis [29!!,30]; PAC, a photoactivatable adenylyl cyclase isolated from Euglena gracilis [39]; Opto-XRs,
rhodopsin/a1-adrenergic or rhodopsin/b2-adrenergic receptor chimeras [42!]; LOV, the phototropin-1 light oxygen voltage domain from Avena sativa
[43!]; SPARK, a synthetic photoisomerizable azobenzene-regulated K+ channel; D-SPARK [46!!], a depolarizing SPARK channel [47]; LiGluR, a light-
activated glutamate receptor [48!!]; Bis-Q, 3,30-bis[a-(trimethylammonium)methyl]azobenzene dibromide [44]; QBr, 3-(alpha-bromomethyl)-30-[alpha-
(trimethylammonium)methyl]azobenzene bromide [45]; AAQ, acryl–azobenzene–quaternary ammonium [52!!]; Glu-Azo, azobenzene–glutamate [54].
Current Opinion in Neurobiology 2009, 19:1–9 www.sciencedirect.com
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glutamate receptors and shaker K+ channels (Banghart et al., 2006; Chambers et al., 
2006; Volgraf et al., 2006).  The PTL approach allows reversible photocontrol of 
neuronal receptors and can be applied to a variety of receptors using both genetic and 
chemical engineering. This technology allows for investigation of the role receptor 
subtypes play in synaptic communication and their function.   
1.5  Alzheimer’s disease 
Alzheimer’s disease (AD) is a chronic, progressive, neurodegenerative disease 
with no cure.  AD is the most common form of dementia and the 6th leading cause of 
death in the United States (Thies et al., 2013).  According to the 2010 US Census and 
the Chicago Health and Aging Project (CHAP) the estimated prevalence of AD is 11% of 
individuals older than 65 years of age have AD, and approximately 32% of people aged 
85 and older have AD (Thies et al., 2013).  Memory impairment is the earliest symptom 
of AD (Nestler et al., 2009; Thies et al., 2013).  As disease progression occurs, cognitive 
impairment increases and eventually patients exhibit complete loss of independence 
(Nestler et al., 2009).  It is estimated that by 2040, there will be 80 million people 
worldwide with AD (Nestler et al., 2009).  The underlying cause or causes and the 
precise sequence of changes in the human brain that trigger the development of 
sporadic AD are unknown (Thies et al., 2013).  Sporadic AD is believed to be a 
multifactoral, slow progressing disease in which the sequence of changes in the brain, 
and the accumulation of pathological proteins, leads to neuronal dysfunction that 
ultimately leads to neuronal death correlating with defects in memory and cognition, the 
symptoms of AD.  These underlying changes are believed to occur between 10 and 20 
years before any memory or cognitive impairment occurs (Gravitz, 2011; Thies et al., 
2013). 
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In 1907, Alois Alzheimer first discovered and characterized the two pathological 
hallmarks of AD: neurofibrillary tangles (NFTs) and amyloid-beta (Aβ) plaques from the 
brain of a diseased patient (Spires-Jones et al., 2009).  NFTs are intracellular 
aggregates of insoluble hyperphosphorylated tau whereas Aβ plaques are extracellular 
aggregates of Aβ produced from the proteolytic cleavage of the amyloid-β precursor 
protein (APP) by β and γ secretases (Figure 1.5) (Andorfer et al., 2003; Bordji et al., 
2010; Mazanetz and Fischer, 2007).  The accumulation of both of these aggregates 
correlate with loss of synapses and neuronal death, which leads to memory impairment, 
cognitive decline, and disease progression.  Intracellular NFTs are believed to impair 
cellular transport of nutrients, cargos, and neurotransmitters where as extracellular Aβ 
plaques are believed to interfere with synaptic communication (Thies et al., 2013).  
Additionally, it has been shown that neuron death leads to brain atrophy, reducing the 
size of an AD brain compared to a normal healthy brain (Santacruz et al., 2005).   
 Significant reduction in postsynaptic density protein 95 (PSD-95), AMPARs, and 
NMDARs are found in the post-mortem brains of AD patients (Keifer and Zheng, 2010; 
Proctor et al., 2011).  This reduction in PSD-95, AMPARs, and NMDARs are associated 
with LTD and deficits in LTP.  The reduction of postsynaptic scaffolding protein, PSD-95, 
is believed to contribute to AMPA receptor dependent LTP deficits in AD (Proctor et al., 
2011).  Loss of synapses and dendritic spines are a common pathology in human 
postmortem brains (Tackenberg et al., 2009).  Additionally, synapse loss precedes 
neuron death indicating disruption of neuronal communication at the synapse is an early 
event in disease progression (Selkoe, 2002).  The extent of disease progression and 
cognitive impairment in AD patients correlates with degree of synaptic loss (Terry et al., 
1991).  Synaptic dysfunction, LTP deficits and memory impairment have been observed 
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Figure 1.5. Pathological Hallmarks of Alzheimer's Disease 
 
Cartoon illustration of degenerating neuron in Alzheimer’s disease with intracellular 
neurofibrillary tangles (NFTs) accumulating in the soma and extracellular amyloid-beta 
(Aβ) plaques.  The presynaptic axon terminal shows shrinkage representative of 
synaptic dysfunction in the degenerating neuron.     
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in AD mouse models before the accumulation of Aβ plaques and NFTs indicating 
synaptic dysfunction underlies the initial development of the disease (Oddo et al., 2003).  
Impaired synaptic plasticity is believed to be one of the earliest and prominent 
pathologies in an AD brain mediating cognitive defects and memory impairment (Penzes 
et al., 2011).  Changes in postsynaptic strength contribute to synaptic dysfunction in AD.  
Decreased synaptic communication and synaptic dysfunction precedes neuronal death.  
 Abnormal accumulation of protein aggregates composed of Aβ plaques and 
NFTs in AD is believed to contribute to synaptic dysfunction and neuron death in late 
stages of AD progression.  Impaired synaptic plasticity and spine loss is associated with 
accumulation of Aβ plaques and NFTs (Tackenberg et al., 2009).  Defects in synaptic 
plasticity, impaired LTP and induced LTD have been associated with Aβ plaque and NFT 
accumulation (Ittner and Gotz, 2011; Malinow, 2012).  Dysfunction of protein 
degradation clearance mechanisms is believed to contribute to AD progression.  
Ubiquitin-proteasome system (UPS) dysfunction, impaired lysosomal degradation, and 
impaired autophagy have been found in AD (Keller et al., 2000; Ling et al., 2009; Min et 
al., 2010; Wolfe et al., 2013).  Since the discovery of these two pathological hallmarks, 
research has focused on trying to prevent the accumulation of aggregated Aβ plaques 
and NFTs in an effort to prevent the progression of AD (Gravitz, 2011).  Each hallmark 
has been extensively studied individually; the focus has been on their separate modes of 
toxicity (Ittner and Gotz, 2011).  Recent evidence has suggested synergistic roles in 
mediating AD progression and possible interactions between Aβ plaques and NFTs 
(Ittner and Gotz, 2011).  Additionally it is believed that both Aβ plaques and NFTs 
directly contribute to defects in synaptic plasticity by impairing LTP and LTD.  
NFTs are aggregates of hyperphosphorylated tau that are mistargeted to both 
the soma and dendritic spines (somatodendritic compartment).  NFTs are implicated in 
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mediating Aβ toxicity and synaptic dysfunction in AD.  Hyperphosphorylated tau in the 
somatodendritic compartment modulates the activity of the src-tyrosine kinase, Fyn, via 
the amino-terminal projection domain of tau (Ittner and Gotz, 2011; Hoover et al., 2010; 
Ballatore et al., 2007; Roberson et al., 2011).  This Fyn-tau interaction is believed to 
target Fyn to dendritic spines (Ittner and Gotz, 2011).  Fyn phosphorylates excitatory 
ionotropic glutamate N-methyl-D-aspartate receptors (NMDAR) subunit 2B (NR2B) 
facilitating interaction with postsynaptic density protein 95 (PSD-95) in the postsynaptic 
compartment (Ittner and Gotz, 2011).  Phosphorylation of NMDAR can result in 
excitotoxic downstream signaling (Ittner et al., 2010).  Hyperphosphorylated tau exhibits 
increased affinity for Fyn, resulting in increased localization of postsynaptic Fyn, 
phosphorylated NMDARs and potentially results in excitotoxic signaling (Bhaskar et al., 
2005; Ittner and Gotz, 2011).  This excitotoxic downstream signaling of NMDARs results 
in neurotoxicity, Ca2+ dysregulation, synapse loss, and increased Aβ toxicity in AD 
(Alberdi et al., 2010; Hoover et al., 2010; Ittner and Gotz, 2011; Malinow, 2012; 
Roberson et al., 2011).   
 Multiple studies have shown that Aβ plaques alter synapse formation, reduces 
surface expression of NMDAR and AMPARs, promotes NMDAR endocytosis, loss of 
dendritic spines, and induces Ca2+ dysregulation and neuronal death by activation of 
NMDARs and AMPARs (Alberdi et al., 2010; Hsieh et al., 2006; Liu et al., 2010; Penzes 
et al., 2011; Snyder et al., 2005).  NMDARs at the synapse are neuroprotective whereas 
extrasynaptic NMDAR are neurotoxic (Hardingham and Bading, 2010).  Compelling 
recent evidence from AD mouse models have implicated that in the absence of tau the 
postsynaptic targeting of Fyn is disrupted, decreasing both NMDAR-mediated 
excitotoxicity and Aβ postsynaptic toxicity (Ittner et al., 2010; Roberson et al., 2011).  
Additionally, hyperphosphorylated aggregated tau has increased association with Fyn 
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and this interaction has been implicated in mediating Aβ toxicity and synaptic 
dysfunction in AD (Bhaskar et al., 2005; Ittner et al., 2010; Roberson et al., 2011).   
 Clearly, these synergistic roles of Aβ plaques and NFTs enhance late stage AD 
progression.  The degree of accumulation of both of these aggregates is an indicator of 
the level of synaptic dysfunction, memory impairment, cognitive decline, and disease 
progression.  Targeting the accumulation of Aβ plaques and NFTs remains controversial.  
Many researchers disagree on which pathological hallmark is key to preventing AD 
progression and focus on targeting proteins involved in the accumulation Aβ plaques 
and NFTs.  Other researchers believe Aβ plaques and NFTs are not the right target 
because they appear after synaptic dysfunction has occurred.  AD is a complex 
multifactoral disease of dying neurons.  The earliest known pathology contributing to AD 
progression is synaptic dysfunction (Oddo et al., 2003; Penzes et al., 2011).  Some 
researchers have recently shifted to identifying and targeting underlying molecular 
factors leading to synaptic dysfunction, and ultimately Aβ plaques and NFTs 
accumulation. 
 A unique class IIb histone deacetylase (HDAC) with cytoplasmic localization, 
HDAC6 (Li et al., 2013; Xu et al., 2011), has emerged as a potential key player in a 
number of neurodegenerative diseases such as Alzheimer’s disease, Huntington’s 
disease, Parkinson’s disease, and Amyotrophic lateral sclerosis (ALS).  HDAC6 may be 
an underlying factor leading to synaptic dysfunction in these neurodegenerative 
diseases.  Unlike other HDACs, HDAC6 has two catalytic deacetylase domains, a Ser 
Glu-peptide repeat domain (SE14), which acts as a cytoplasmic retention signal, and a 
BUZ domain that binds polyubiquitinated proteins (Ding et al., 2008; Li et al., 2013).  
HDAC6 is a versatile multifunctional enzyme responsible for deacetylating key proteins 
involved in protein degradation pathways, cellular stress, and cytoskeletal dynamics 
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(d'Ydewalle et al., 2012; Li et al., 2013; Parmigiani et al., 2008; Zhang et al., 2013).  The 
role of HDAC6 in neurodegenerative disease is controversial as it is unclear if HDAC6 
functions as neuroprotective or neurotoxic.   
 HDAC6 deacetylates two important cytoskeletal proteins, α-tubulin subunits of 
microtubules and cortactin, a filamentous actin binding partner (Hubbert et al., 2002; 
Zhang et al., 2007).  Deacetylation of α-tubulin renders microtubules less stable and 
leads to depolymerization (Hubbert et al., 2002; Matsuyama et al., 2002).  Deacetylation 
of cortactin inhibits binding to filamentous actin leading to actin depolymerization, 
impairing cell motility (Kaluza et al., 2011; Zhang et al., 2007).  HDAC6 alters 
cytoskeletal dynamics by influencing depolymerization of key proteins involved in 
synaptic remodeling.  
 HDAC6 is an integral protein with diverse functions in mediating and coordinating 
cellular response to the cytotoxic accumulation of misfolded and aggregated proteins by 
interacting with polyubiquitinated proteins when UPS degradation is impaired by 
activating both autophagy and heat-shock proteins (Kalveram et al., 2008; Matthias et 
al., 2008; Pandey et al., 2007).  Thus, HDAC6 is an important protein for coordinating 
the sequestration of protein aggregates and their clearance.  Another cellular stress 
response that HDAC6 has is in redox regulation.  Cellular stress leading to accumulation 
of reactive oxygen species can be detrimental to cell survival and are common in 
neurodegenerative diseases.  HDAC6 deacetylates two redox regulatory antioxidant 
enzymes peroxiredoxin I (PRXI) and II (PRXII), which when deacetylated function to 
reduce H2O2 (Parmigiani et al., 2008).    
  Evidence from post-mortem AD human brains, AD animal models, and AD 
studies suggest that HDAC6 may be an underlying molecular factor that becomes 
neurotoxic when upregulated and thus contributes to AD pathology and progression.  In 
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fact, immunoblots from post-mortem human AD brains have shown that HDAC6 protein 
levels are increased 52% in the cortex and 91% in the hippocampus compared to age-
matched control brains (Ding et al., 2008).  HDAC6 is known to mediate and coordinate 
cellular response to the cytotoxic accumulation of misfolded and aggregated proteins 
and in AD misfolded aggregated proteins accumulate yet UPS dysfunction, impaired 
lysosomal degradation, and impaired autophagy have been shown in AD (Keller et al., 
2000; Ling et al., 2009; Min et al., 2010; Wolfe et al., 2013).  A number of recent 
publications have illustrated that reduction or loss of HDAC6 reduces cognitive deficits in 
a mouse model for AD, alleviates abnormal tau accumulation, and rescues 
phosphorylated tau-mediated microtubule instability (Cook et al., 2012; Govindarajan et 
al., 2013; Xiong et al., 2013).  This data suggest that increased expression of HDAC6 is 
neurotoxic in AD and that targeting HDAC6 may be a potential strategy for preventing 
the progression of AD.  The question remains whether HDAC6 is an underlying 
molecular factor leading to synaptic dysfunction, and ultimately NFTs and Aβ plaques 
accumulation.  
 HDAC6 has previously been shown to interact with a key protein phosphatase, 
protein phosphatase 1 (PP1), via HDAC6’s second catalytic domain (Brush et al., 2004).  
PP1 is an important phosphatase responsible for removing phosphate groups from 
proteins, regulating their function.  One protein regulated by PP1 is tau.  Tau is a 
microtubule-associated protein (MAP), primarily expressed in neurons that promote 
microtubule assembly and stabilization (Iqbal et al., 2005).  PP1 has been shown to 
interact and dephosphorylate tau, increasing the affinity of tau for microtubules and 
stabilizing them (Liao et al., 1998).  Dysregulated tau homeostasis results in increased 
tau phosphorylation and subsequently abnormally hyperphosphorylated tau with reduced 
affinity for microtubules and this form of hyperphosphorylated tau forms NFT in AD 
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(Andorfer et al., 2003; Spires-Jones et al., 2009).  Interestingly, a domain-selective 
small-molecule enzyme inhibitor tubacin, targets the second catalytic domain of HDAC6 
preventing HDAC6 from deacetylating α-tubulin (Haggarty et al., 2003).  In vitro inhibition 
of HDAC6 by tubacin was shown to attenuate tau phosphorylation, however, it is unclear 
if tubacin disrupted an HDAC6-PP1 interaction enabling PP1 to dephosphorylate tau 
(Ding et al., 2008).  Additionally, shRNA-mediated knockdowns of HDAC6 were shown 
to attenuate tau phosphorylation suggesting HDAC6 regulates PP1 activity (Ding et al., 
2008).  These data suggest that overexpression of HDAC6 alters PP1 enzymatic activity 
thus creating an imbalance of kinase and phosphatase activity that leads to the aberrant 
hyperphosphorylation of tau.  A proposed model of HDAC6 mediated AD pathology and 
synaptic dysfunction is shown in Figure 1.6.  
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Figure 1.6. Model of HDAC6 Mediated Alzheimer's Disease Pathology 
 
Cartoon illustration of HDAC6 mediated AD pathology and synaptic dysfunction in 
degenerating neuron.  An increase in HDAC6 protein levels leads to decreased PP1 
activity.  The changes in HDAC6 protein levels and PP1 activity lead to an increase in 
pathological hyperphosphorylated tau assembling into intracellular neurofibrillary tangles 
(NFTs) which accumulates in the soma of the degenerating neuron along with 
extracellular accumulation of amyloid-beta (Aβ) plaques.  These changes ultimately lead 
to synaptic dysfunction in the degenerating neuron.    
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1.6  Motivation 
 The overall goals of this thesis are to develop novel strategies to understand 
underlying mechanisms of synaptic communication, and learning and memory.  The 
mammalian brain is a complex system with very few tools to study how memories are 
formed, the function of receptor subtypes, and changes that lead to disease.  By 
developing novel strategies to study neural activity using pharmacology tools and 
genetics, we can perturb the system and discover the role of receptor subtypes in 
controlling neural activity and the role of specific proteins in disease progression.  By 
developing novel photoswitchable tethered ligands photocontrol of specific ion channels 
can be achieved, allowing the discovery of the role those receptors have in regulating 
learning and memory at the synapse.  
 Efforts by scientists and pharmaceutical companies to target AD pathology and 
progression late in the disease have been unsuccessful in preventing disease 
progression in humans.  Early changes that lead to AD pathology and the discovery of 
underlying molecular factors leading to synaptic dysfunction and AD progression have 
been elusive.  Most of what is known about AD progression and pathology comes from 
post-mortem adult late-stage AD brains and animal models developed to investigate 
plaque and tangle modes of toxicity, disease progression and memory impairment and 
cognitive decline.  Both models are only snapshots of the disease pathology.  The goal 
here is to identify key changes that lead to the pathological hallmarks of AD and early 
changes that correlate with synaptic dysfunction by developing a neuron cell culture 
model system. 
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2 CHAPTER 2 
PHOTOCONTROL OF GABAA RECEPTORS 
The work presented in this chapter was an interdisciplinary collaboration project between 
members of James J. Chambers laboratory at UMASS Amherst, which included Devaiah 
Vytla and members of Richard H. Kramer’s laboratory at University of California 
Berkeley, which included Wan-Chen Lin, Christopher M. Davenport, Alexandre Mourot, 
and Caleb M. Smith.  Parts of this chapter are from several manuscripts in preparation or 
under current review. 
2.1  Introduction 
 Controlling synaptic neurotransmission with a phototethered ligand (PTL) has 
been utilized to photosensitize glutamate channels, K+ channels, and nicotinic 
acetylcholine receptors (Banghart et al., 2004; Lester et al., 1980; Volgraf et al., 2006).  
The major inhibitory neurotransmission in the brain is controlled by activation of the 
GABA receptor by GABA neurotransmitter.  The GABA receptor is an untouched target 
for a PTL.  Ionotropic GABAA receptors are important drug targets in the treatment of 
anxiety disorders, sleep disorders, epilepsy and many drugs of abuse, including alcohol, 
barbiturates, and benzodiazepines (Jones-Davis and Macdonald, 2003; Atack, 2005; 
Mohler, 2006; Korpi et al., 2002; Rudolph and Knoflach, 2011; Smith and Rudolph, 
2012).  Nineteen genes encoding GABAA receptor subunits have been identified: α1-6, 
β1-3, γ1-3, δ, ε, θ, π, and ρ1-3 (Barnard et al., 1998; Olsen and Sieghart, 2008).   Subunit 
composition of GABAA receptor subtypes determines subcellular localization, expression 
patterns, function and pharmacology (Olsen and Sieghart, 2008).  The most common 
subunit composition for GABAA receptors are two subunits of α and two β and an 
additional subunit of γ or δ (Belelli and Lambert, 2005).  The α-subunit is important for 
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receptor localization and channel gating kinetics, and with the β-subunit forms the 
GABA-binding site (Mohler, 2006; Rudolph and Knoflach, 2011).  GABAA receptors 
containing the α1-subunit are the most common α-isoform in the brain (Olsen and 
Sieghart, 2008).  The function of two α-isoforms, α1 and α5 subunits, were of particular 
interests to us due to their distinct expression patterns in the hippocampus and 
pharmacology.  GABAA receptors containing α1-subunits are believed to detect 
presynaptically released GABA and mediate transient “phasic” inhibition, where as 
GABAA receptors containing α5-subunits are believed to mediate persistent “tonic” 
inhibition (Farrant and Nusser, 2005).  
 Identifying the physiological function of receptor subtypes in synaptic 
neurotransmission has been elusive due to the paucity of current pharmacological tools 
that target specific subtypes and inability to prevent compensatory changes in gene 
expression of other isoforms or related proteins in subtype specific gene-knockout 
animals (Kralic et al., 2002; Mohler, 2006; Ortinski et al., 2006; Rudolph and Mohler, 
2004; Rudolph and Knoflach, 2011).  To overcome these obstacles in discovering the 
function of GABAA receptor subtypes in synaptic neurotransmission, we developed a 
series of photochemical tools for precise and selective manipulation of specific subtypes 
of GABAA receptors.  We designed a chemical-genetic approach to enable target-
specific photocontrol of neuronal inhibition.  We engineered light-regulated GABAA 
receptors (LiGABAAR) by employing a PTL strategy for creating light-sensitive α1- and 
α5-GABAA receptors.    
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2.2  Results 
2.2.1  PTL design and photoisomerization of MAM-6 
 The design of a PTL that targeted GABAA receptor was based on previous 
GABAAR probes in which the amino group of a potent GABAA receptor agonist muscimol 
was linked to biotin or a fluorophore (Vu et al., 2005).  The PTL design contained an 
azobenzene photoswitch, which allowed photoisomerization from a trans confirmation 
upon irradiation with 500 nm to cis conformation upon irradiation with 380 nm.  The 
azobenzene photoswitch enabled the conformation of the PTL to change from an 
extended trans conformation or retracted cis conformation.  Additionally, our PTL design 
contains a maleimide group for covalent attachment to genetically engineered cysteine 
mutant GABAA receptors.  The PTL was named MAM-6 for malemide, azobenzene, and 
muscimol linked by a 6-carbon spacer.  This spacer enables muscimol to enter the 
GABA-binding pocket.  An illustration of the photoisomerization of MAM-6 is shown in 
Figure 2.1.    
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Figure 2.1. Photoisomerization of MAM-6 
 
Scheme depicting the photoisomerization of MAM-6.  The PTL reversibly 
photoisomerizes between elongated trans confirmation upon irradiation with 500 nm 
visible light (green) and retracted cis confirmation upon irradiation with 380 nm ultraviolet 
light (violet). 
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2.2.2  Attachment sites and photoregulation of MAM-6 in α1- and α5-subunit 
 Potential PTL attachment sites for optimal photoregulation were screened using 
the α1-containing GABAA receptor, the most common isoform in the brain.  We focused 
on a region of the α1 subunit that is close to the GABA-binding pocket, a region between 
the α- and β-subunits.  Residues facing towards the GABA-binding site were chosen as 
PTL attachment sites, residues in yellow were cysteine substituted to make a library of 
single-cysteine mutant α1-subunits (Figure 2.2A).  Initial testing of the activity of the PTL 
was done in an exogenous system where cysteine mutant receptors of interest were co-
expressed with wild-type β2-subunit to form functional receptors in Xenopus oocytes.  
Muscimol is an agonist of GABAA receptors, yet we found mutant receptors tethered with 
MAM-6 were not activated by irradiation with either 380 nm or 500 nm light but were 
inhibited (Figure 2.2B).  The amplitude of the GABA response decreased under 500 nm 
visible light conditions when MAM-6 was in an extended trans conformation and the 
current increased when MAM-6 was in a retracted cis conformation under 380 nm 
ultraviolet light conditions (Figure 2.2B).  Thus, tethered MAM-6 functioned as an 
antagonist under 500 nm visible light conditions.  
 Next, we made a library of single-cysteine mutant α5-subunits that were 
homologous to screened residues of α1-subunits facing towards the GABA-binding site 
(Figure 2.2A, Figure 2.2C).  We screened for photoregulation to identify the optimal PTL 
attachment site in α1- and α5 cysteine mutant receptors.  Tethered MAM-6 enabled 
photoregulation of both α1- and α5-cysteine mutant receptors (Figure 2.2D) as the 
photoregulation index, which is a ratio of GABA-elicited currents in 380 nm vs. 500 nm 
(I380/I500).  The identified PTL attachment sites that substantially photoregulated GABA-
elicited current were (α1: S68C, T121C, T125C and α5: S72C). 
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Figure 2.2. PTL Attachment Sites and Photoregulation of Engineered α1- and α5 
Receptors 
 
A) Homology model of α1β2 subunits showing MAM-6 attachment sites with cysteine 
mutated residues in yellow and the GABA binding site with docked muscimol in red.  
B) Representative traces from Xenopus oocytes expressing α1(S68C)β2 treated with 
MAM-6 showing reversible photoregulation of GABA-elicited current.   
C) Sequence alignment with residues chosen for cysteine substitution mutation sites 
shown in red for α1 and α5.  Residues homologous to tested α1 cysteine-mutants were 
chosen as sites for cysteine substitution in α5.  
D) Photoregulation after MAM-6 treatment of α1 or α5 mutant receptors expressed in 
Xenopus oocytes. Each mutant was co-expressed with wild-type β2 subunit to form the 
GABA-binding site.  Cysteine-mutated residues for α1 or α5 mutant receptors indicated 
in blue.  The ratio (mean ± SEM) of current amplitude (from 3 µM GABA, -80 mV) elicited 
from irradiation with 380 nm vs. 500 nm (I380/I500) light was used as an index of 
photoregulation, where a ratio of 1 indicates no light sensitivity of the tested cysteine-
mutant receptor. 
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Supplemental Figure 3.  Photosensitization of !5-containing GABAA receptors. 
(a) A segment of sequence alignment (!1 vs. !5).  Residues homologous to the tested !1-
mutants were chosen as cysteine mutation sites (red).
(b) Photoregulation f MAM-6 ttached !5 mutants, co-expressed with wild-type "2 in 
oocytes.  Currents elicited by 3 #M GABA were measured in 380 nm and 500 nm by two-
electrode voltage-clamp Holding potential = –80 mV. 
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2.2.3  Trans MAM-6 inhibits LiGABAAR after PTL treatment 
 Next, we determined if binding of the PTL altered receptor sensitivity to GABA-
elicited current.  Whole-cell patch clamp electrophysiology of GABA-elicited current from 
Xenopus oocytes expressing α1(T125C)β2 showed that GABA responses before and 
after PTL attachment are similar to GABA responses in the retracted cis conformation 
whereas in the extended trans conformation GABA responses are reduced after PTL 
attachment (Figure 2.3).  The GABA responses to 300 µM GABA before and after PTL 
attachment indicate negligible changes in receptor activity during the experiment.  Only 
in the presence of externally applied GABA was the receptor activated, irradiation with 
light did not trigger receptor activation.  Attachment of the PTL to genetically engineered 
cysteine mutant receptors created light-regulated GABAA receptors (LiGABARs). 
  To determine if cysteine substitution or PTL attachment affected receptor 
sensitivity to GABA we investigated GABA sensitivity of untreated, MAM-6 treated α-
cysteine engineered mutant receptors to that of untreated wild-type α1β2 receptors or 
wild-type α5β2 receptors.  The effect of MAM-6 attachment or engineered cysteine 
residue substitution on receptor function was evaluated by quantifying the change in 
current ratio elicited from responses to 3 µM to 3 mM GABA (Table 1).  We determined 
that the following cysteine mutation sites for α1: 41, 68, 171 had lower sensitivity to 
GABA compared to wild-type and therefore these cysteine mutants were not optimal 
sites for PTL attachment to study receptor subtype function in neurons because receptor 
sensitivity was altered (Table 1).  Further, the α1(T125C) mutation was chosen as the 
optimal PTL attachment site because it allowed substantial photoregulation of α1 GABA 
receptors without altering receptor sensitivity to GABA before or after PTL attachment 
(Table 1).   For α5 GABA receptors we determined the α5(S72C) mutation as the optimal 
PTL attachment site.   
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Figure 2.3. Attachment of Trans MAM-6 Inhibits Engineered GABAA 
Receptors 
 
Representative trace of GABA responses from a Xenopus oocyte expressing 
α1(T125C)β2.  The oocyte was first exposed to 3 µM GABA followed by 300 µM GABA, 
then treated with 50 µM MAM-6 for 10 minutes to allow for cysteine tethering of the PTL. 
After MAM-6 treatment the oocyte was irradiated with 500 nm light during 3 µM GABA 
exposure followed by irradiation with 380 nm light during 3 µM GABA exposure, and  
finally treatment with 300µM GABA during irradiation with 380 nm light. 
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B.3. Molecular Modeling
B.4. Synthesis of MAM-6, MAM-0, and MAB-0
C. Supplementary References
A. Supplementary Data
Fig. S1. Trans MAM-6 inhibits a mutant GABAAR after conjugation. An oocyte 
!"#$!%%&'()*+,-+./012.)34%)5!%5!6)3&57)8)9:)4'6)8;;)9:)<=>=),black traces on the left).   
Th  oocyte was then treated with 50 µM MAM-6 f r 10 minutes. After MAM-6 tr atment, 
the current at 3 µM GABA a reduced in 500-nm (green trace) but not in 380-nm light 
(middle purple trace). The responses evoked by 300 ?M GABA before and after MAM-6
attachment indicated that the change in receptor activity was negligible over the course of 
the experiment. Neither 380-nm nor 500-nm light triggered receptor activation in the 
absence of externally applied GABA.
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Table 1: GABA sensitivity of untreated and MAM-6 treated engineered α-mutants 
 
a. Current ratio was measured at 3 µM GABA (500 nm vs. 380 nm). 
b. The effect of MAM-6 attachment or cysteine substitution on receptor function was 
evaluated by the change in current ratio at 3 µM GABA vs. 3 mM GABA. The 
EC50 of wild-type α1β2 receptors is ~3 µM. 
c. The mutant receptor’s sensitivity to GABA is lower than that of the wild-type α1β2 
receptors (indicated by I3µM/I3mM). 
d.  The receptor’s sensitivity to GABA is reduced in both 500 nm and 380 nm lights 
after MAM-6 attachment. 
e.  The receptor’s sensitivity to GABA is unaltered in 380 nm light after MAM-6 
attachment.  This feature makes α1(T125C) the best mutant for downstream 
applications in neurons. 
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Table S1. The GABA Sensitivity of Untreated and MAM-!"#$%&#%'"(-Mutants.
mutation 
site
MAM-6 attached receptor untreated receptor
commentsI500/I380
(mean ± SEM)a trials
I3µM/I3mM (380 nm)
(mean ± SEM)b trials
I3µM/I3mM
(mean ± SEM)b trials
!1
wild-
type
1.08 ± 0.02
(untreated) 9 -- -- 0.46 ± 0.03 9
41 0.62 ± 0.03 10 0.41 ± 0.03 9 0.33 ± 0.03 3 c
68 0.47 ± 0.05 8 0.17 ± 0.03 4 0.34 ± 0.03 3 c,d
121 0.52 ± 0.03 14 0.34 ± 0.03 14 0.49 ± 0.02 4 d
125 0.60 ± 0.03 10 0.44 ± 0.07 7 0.45 ± 0.05 4 e
171 0.63 ± 0.03 4 0.20 ± 0.01 4 0.20 ± 0.01 3 c,d
!5
wild-
type
1.01 ± 0.01
(untreated) 3 0.43 ± 0.01 7
72 0.95 ± 0.10 15 0.22 ± 0.02 11 0.39 ± 0.00 3
a. Curr nt ratio was measured at 3 µM GABA (500 nm vs. 380 nm).
b. The effect of MAM-6 attachment or cysteine substitution on receptor function was evaluated by the change 
of current ratio at 3 µM vs. 3 mM GABA. As a reference, EC50 of the wild-!"#$%&'()%*+%,-%./%01*2+!%23456
c. The mutant receptor’s sensitivity to GABA is lower than that of the wild-type (indicated by I3µM/I3mM).
d. The receptor’s sensitivity to GABA is reduced in both 500-nm and 380-nm lights after MAM-6 attachment.
e. The receptor’s sensitivity to GABA is unaltered in 380-nm light after MAM-6 attachment.  This feature 
789$+%&'0:');<5%!=$%>$+!%7?!8@!%132%A34@+!2$87%8##B*C8!*3@+%*@%@$?23@+6
 
B. Supplementary Materials and Methods
B.1. Plasmid and virus preparation
! Wild-type and mutant cDNAs
The cDNAs of rat GABAAD% &'% 8@A% () subunits (wild-type and mutants) are in 
vector pGH19 (for oocytes), pCDNA3.1 (for HEK293T cells and oocytes), or pUNIV (for 
HEK293T cells). The cysteine mutants &'(K70C) and &'(D123C) and wild-type subunits 
(&'%8@A%()) were obtained in vector pGH19 from Professor Cynthia Czajkowski (University 
of Wisconsin, USA). The wild-!"#$% &;% +?>?@*!% 48+% 3>!8*@$A% *@% E$C!32% #DFG% 1237% H26%
Hartmut Luddens (University of Mainz, Germany). The wild-!"#$%I)J%+?>?@*!%was obtained 
in vector pUNIV from Professor Cynthia Czajkowski. :=$%K$@$+%31%&%8@A%(%+?>?@*!+%were 
sub-cloned into vector pCDNA3.1 for expression in HEK293T cells. Other cysteine mutants
were prepared by site-directed mutagenesis in the wild-!"#$% &'% and &5 clones (in 
pCDNA3.1). Mutations were confirmed by sequencing.
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2.2.4  Identification of critical PTL components for LiGABAAR control 
 To determine the critical components required for the PTL to photoregulate 
GABA receptors of interest we altered the structure of the MAM-6 PTL design.  Both the 
muscimol ligand and spacer moieties of MAM-6 were altered and the resulting PTLs 
were tested for their ability to photoregulate 10 µM GABA sensitivity of α1(T125C) 
GABAA receptors or α5(S68C) GABAA receptors.  Muscimol is negatively charged at 
physiological pH, enabling receptor binding.  Consistent with this mechanism, replacing 
muscimol with a neutral analogue 4-hydroxylbenzylamine reduced the photoregulation 
effect in α1(T125C) GABAA receptors; this PTL was named MAB-6 (Figure 2.4A, Figure 
2.4B).  Photoregulation was nearly completely suppressed in α1(T125C) GABAA 
receptors when the  6-carbon spacer of MAM-6 was removed; this PTL was named 
MAM-0 (Figure 2.4A, Figure 2.4B).  Surprisingly, removal of the 6-carbon spacer and 
substituting muscimol with neutral analogue 4-hydroxylbenzylamine (MAB-0), increased 
the photoregulation effect in α1(T125C) GABAA receptors, resulting in an effect greater 
than that by MAM-6, suggesting that the muscimol ligand was not a required component 
of the PTL design for photoregulation (Figure 2.4A, Figure 2.4B).  Interestingly, 
α5(S68C) GABAA receptors were only photoregulated with MAM-6 attachment, 
suggesting both a flexible linker and a negatively charged ligand are required for 
photoregulation of α5 receptors (Figure 2.4C).  In summary, screening of engineered 
cysteine-mutant receptors and PTLs revealed the best combination for creating light-
regulated GABAA receptors (LiGABARs) was α1(T125C) tethered to MAB-0 and 
α5(S68C) tethered to MAM-6.    
 The strong photoregulation by MAB-0 suggests that its ligand binds strongly to the 
GABA-binding pocket when the azobenzene is photoswitched to the trans isomer 
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suggesting MAB-0 prevents GABA binding by blocking the GABA-binding site.  To 
investigate the increased photoregulation effect of MAB-0 in α1(T125C) GABAA 
receptors, we used molecular modeling to dock trans and cis MAB-0.  Docking trans 
MAB-0 in a homology model of α1(T125C)β2 dimer suggested that the PTL spans the 
GABA binding site and the binding pocket (Figure 2.4D, top).  Aromatic residues in the 
GABA-binding pocket are indicated in yellow (Figure 2.4D).  Trans-to-cis isomerization of 
azobenzene retracts MAB-0 from the GABA binding site subsequently relieving receptor 
antagonism (Figure 2.4D, bottom).   
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Figure 2.4. Critical Components of PTL for Photocontrol of LiGABAARs 
 
A)  Series of PTLs 
B)  Photoregulation of  α1(T125C)β2 receptors with MAM-6, MAB-6, MAM-0 and MAB-0.  
The ratio (mean ± SEM) of current amplitude (elicited from 10 µM GABA, -70 mV, 
HEK293T cells) elicited from irradiation with 380 nm vs. 500 nm (I380/I500) light was used 
as an index of photoregulation, where a ratio of 1 indicates no light sensitivity of the 
tested cysteine-mutant receptor. 
C) Photoregulation of  α5(S68C)β2 receptors with MAM-6, MAB-6, MAM-0 and MAB-0.  
The ratio (mean ± SEM) of current amplitude (elicited from 10 µM GABA, -80 mV, 
Xenopus oocytes) elicited from irradiation with 380 nm vs. 500 nm (I380/I500) light was 
used as an index of photoregulation, where a ratio of 1 indicates no light sensitivity of the 
tested cysteine-mutant receptor. 
D)  Docking pose of trans or cis MAB-0 in a homology model of α1β2 dimer.  A positional 
constraint was used to mimic tethering at α1(T125C) shown in orange.  Aromatic 
residues in the GABA-binding pocket are in yellow.   
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Fig. S2. !"#$%&'&()%&*$+*'+%,#+*-%&.)/+012+'*3+456789:;< MAM-6, MAB-6, and MAM-0
were tested in Xenopus oocytes held at –80 mV (  = 15, 8, and 4, respectively). MAB-0 was 
tested in HEK293T cells held at –70 mV (n = 3). Currents were elicited by 3 µM GABA in 
either 380-nm or 500-nm light. The ratio of current amplitude in 380 nm vs. in 500 nm was
used as an index of photoregulatio . A rati  of 1 indicates n  light sensitivity of the tested 
receptor. Data are presented as mean ± S.E.M.
!1(T125C)
MAB-0
!5(S72C)
MAM-6
A B
>10 "M gabazine
Fig. S3. LiGABARs photoregulate holding currents in cultured hippocampal neurons.
(A) A representative trace showing reversible photoregulation of the baseline level when a 
LiGABAR-containing neuron was held at –60 mV. Photoregulation was abolished, 
accompanied by a rise of the baseline level and a decrease in the baseline noise, after the 
addition of gabazine. (B) Group data (mean ± S.E.M., 6 cells each) for the photoregulation 
!"#$!%&'()#*+,,-(.#'(#(-+,!(/#0'.$#12- !,#13-LiGABAR.
Trans  
MAB-0 
Cis 
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2.2.5  Photoregulation of mIPSC of α1- and α5-GABAA receptors  
 Once the optimal PTL design and attachment site for α1- and α5-GABAA 
receptors was determined, we investigated if synaptic inhibition in primary neurons could 
be controlled optically with these LiGABAARs.  These experiments were to test if α1- and 
α5-GABAA enable photoregulation of phasic and tonic inhibition.  Primary dissociated 
cultures of hippocampal neurons isolated from rat brains were transfected with a bi-
cistronic construct encoding either α1(T125C) or α5(S72C), along with eGFP as a 
transfection marker.  When these neurons were synaptically active, between DIV 17-21 
days, they were treated with MAB-0(α1) or MAM-6(α5) for 15 minutes.  To investigate 
phasic inhibition, we acquired whole-cell patch clamp electrophysiology recordings of 
endogenous mini inhibitory postsynaptic currents (mIPSCs) from neurons expressing 
α1(T125C) or α5(S72C) after PTL treatment (Figure 2.5A).  Both α1(T125C) or 
α5(S72C) LiGABAARs enabled photoregulation of endogenous mIPSCs.  The amplitude 
of the mIPSC were increased upon irradiation with 380 nm light when the PTL was in the 
retracted cis conformation whereas the amplitude decreased upon irradiation with 500 
nm light when the PTL was in the extended trans conformation (Figure 2.5A, Figure 
2.5B).  To quantify the amount of photoregulation, the average mIPSC when the PTL 
was in cis or trans conformation was calculated.  Neurons with α1(T125C)-LiGABAARs, 
cis-to-trans photoisomerization had a 38 ± 2% decrease in peak amplitude and a 57 ± 
4% decrease in total charge transfer (n = 6, P < 0.001; Figure 2.5B, Figure 2.5C).  
Neurons with α5(S72C) LiGABAARs cis-to-trans photoisomerization had a 29 ± 3% 
decrease in peak amplitude and 34 ± 4% decrease in total charge transfer (n = 6, P < 
0.001; Figure 2.5B, Figure 2.5C). 
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Figure 2.5. LiGABAAR Mediated Photoregulation of mIPSCs 
 
A) Representative traces of mIPSC recordings from a cultured hippocampal neuron 
containing MAB-0 tethered to α1(T125C) subunits (top) or MAM-6 tethered to α1(S68C) 
subunits (bottom).  Neurons were held at -60 mV.  To convert the PTL to its cis isomer, 
cells were exposed to 380 nm light for 5 seconds, then no light where the majority of the 
PTL remains in the cis conformation.   
B) Representative average mIPSC traces when the PTLs were in the trans (green trace) 
or cis (violet trace) conformation from the cells shown in A.  MAB-0 tethered to 
α1(T125C) subunits (top panel) or MAM-6 tethered to  α1(S68C) subunits (bottom 
panel). 
C) Group data (mean ± S.E.M.) of mIPSC photoregulation in cultured hippocampal 
neurons (n = 6 for each isoform).  The degree of photoregulation was quantified as the 
percent decrease (in peak amplitude or charge transfer) when the PTL was 
photoswitched from cis to trans.      
 
!"#"$"
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2.2.6  MAB-O selectivity   
 Control experiments were completed to confirm that PTL were target-specific and 
did not photoregulate or confer light sensitivity on wild-type neurons.  These control 
experiments were completed to confirm off-target receptors were not altering their 
function in response to light.  These controls were necessary because the PTL contains 
a maleimide moiety could potentially allow for cysteine tethering to receptors containing 
endogenous cysteine residues.  Treatment of PTL on wild-type neurons did not 
photoregulate wild-type GABAA receptors, ionotropic glutamate receptors, or voltage-
gated channels, confirming that photocontrol is specific to the engineered LiGABAAR 
(Figure 2.6).  The designed PTL only photosensitizes the mutant receptor containing the 
α subunit of interest. 
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Figure 2.6. MAB-0 Treatment Does Not Photosensitize Endogenous Ligand-gated 
or Voltage-gated Ion Channels 
  
A) Average mIPSC traces from representative neuron following MAB-0 treatment does 
not photosensitize endogenous GABAARs in cultured hippocampal neurons.  I500/I380 = 
1.00 ± 0.02 (Vhold = –60 mV; n = 3, P = 0.87). 
B) Average mEPSC from representative neuron following MAB-0 treatment does not 
photosensitize endogenous GABAARs in cultured hippocampal neurons.  I500/I380 = 0.97 
± 0.10 (Vhold = –70 mV; n = 4, P = 0.64). 
C) MAB-0 treatment does not photosensitize endogenous AMPARs in a hippocampal 
slice. Evoked EPSC traces from a CA1 pyramidal neuron are shown.  I500/I380 = 1.02 ± 
0.01 (Vhold = –70 mV; n = 4, P = 0.2). 
D) MAB-0 treatment does not photosensitize endogenous NMDARs in a hippocampal 
slice. Evoked EPSC traces from a CA1 pyramidal neuron are shown. Currents were 
measured 100ms after the stimulus.  I500/I380 = 0.95 ± 0.04 (Vhold = +40 mV; n = 3, P = 
0.3). 
E) MAB-0 treatment does not photosensitize endogenous voltage-gated Na+ channels.  
Inward currents (elicited by a 200-ms depolarization to –10 mV) from a representative 
neuron are shown.  I500/I380 = 0.99 ± 0.05 (Vhold = –70 mV; n = 4, P = 0.87). 
F) MAB-0 treatment does not photosensitize native voltage-gated K+ channels. Voltage-
gated K+ currents (elicited by a 200-ms depolarization to +40 mV) from a representative 
neuron are shown.  I500/I380 = 0.98 ± 0.05 (Vhold = –70 mV; n = 4, P = 0.43). 
 
All traces in 380 nm and 500 nm are shown in violet and green colors, respectively.   
 
 
!
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2.2.7  Photocontrol of neuron excitability  
 The goal of designing PTL to target subtype specific α receptors was to discover 
the function of GABAA receptor subtypes in synaptic neurotransmission using 
photochemical tools for precise and selective manipulation of specific subtypes of 
GABAA receptors.  GABAA receptors have a crucial function in preventing runaway 
neuronal excitation.  Pharmacological inhibition or knock-out of GABAA receptors are 
known to alter GABAA function and result in epileptic brain activity.  To determine if 
epileptic activity can be induced by photo-antagonizing α1(T125C) LiGABAAR in intact 
brain tissue we introduced α1(T125C) LiGABAAR into hippocampal brain slices using 
AAV.  After MAB-0 treatment we applied a train of presynaptic stimuli and recorded 
action potential firing of neurons irradiated with 380 nm and 500 nm light.  Photocontrol 
of neural inhibition of α1(T125C) LiGABAAR  irradiated with 500 nm light where the PTL 
was in an extended confirmation led to photocontrol α1(T125C) LiGABAAR  that 
prevented of action potential firing, a characteristic of epileptiform activity (Figure 2.7).  
Irradiation of the α1(T125C) LiGABAAR with 380 nm reversed this effect enabling action 
potential firing and prevention of epileptic activity (Figure 2.7).  
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Figure 2.7. LiGABAA Receptors Enable Photocontrol of Neuron Excitability 
 
Whole-cell current-clamp recording of CA1 pyramidal neuron expressing α1(T125C) 
receptors treated with MAB-0 enabled photocontrol of neuron excitability.  Irradiation 
with 500 nm light resulted in an “epileptic” plateau preventing action potential firing that 
was reversed upon irradiation with 380 nm light. Traces in 380 nm shown in violet and 
500 nm are shown in green. 
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2.3  Discussion 
 We developed a series of LiGABAAR that enable light-controlled inhibitory 
neurotransmission.  The α1- and α5-LiGABAARs developed here are distinct from 
previously developed photochemical tools for manipulating neural inhibition such as 
caged GABA in that LiGABARs allow specificity and for native forms of inhibitory 
neurotransmission to be controlled by light.  The LiGABAARs developed here provide a 
unique opportunity for spatiotemporal precision to investigate the underlying 
mechanisms of subtype-specific neural inhibition.  Designing PTLs and genetically-
engineering GABAA receptors enabled specific spatiotemporal precision to investigate 
and manipulate receptor-subtype contributions in inhibitory neurotransmission.  We have 
developed a method for photocontrolling GABAA receptors that is fast, reversible and 
subtype-specific. 
 PTLs have the ability to target surface exposed cysteines on endogenous 
receptors and engineered-cysteine substituted receptors.  The results of our 
experiments showed that our PTLs only conferred light-sensitivity and photocontrol on 
engineered receptors.  Wild-type GABAA receptors and other off-target ion-channels 
were not photoregulated by these PTLs demonstrating that the PTLs in our experiments 
were specific to receptor subtypes of interest.  Further, cysteine substitutions of α1 and 
α5 GABAA receptors with subsequent PTL attachment enabled photocontrol of GABAA 
receptors.  PTL attachment sites had varying degrees of photocontrol.  The optimal PTL 
attachment site and subsequent PTL attachment enabled substantial photocontrol of 
inhibitory neurotransmission without altering the receptors GABA sensitivity. 
 The results illustrate tethered muscimol acts as an antagonist when the PTL is 
irradiated with 500 nm light on genetically-engineered cysteine substituted GABAA 
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receptors.  The PTL design was based on reports that muscimol conjugates in which the 
amino group was linked to biotin or a fluorophore remained a GABAA receptor agonists 
(Vu et al., 2005).  Receptor antagonism by tethered muscimol may be the result of 
changes to the moiety that render unable to induce protein conformation changes 
required for channel gating.  Loss of the critical ammonium group of agonists are know 
to prevent hydrogen bonding which prevents changes required for channel gating 
(Cromer et al., 2002).  The tethering of muscimol due to N-acylation leads to the loss of 
an ammonium group that may disrupt conformational changes required for channel 
gating.  Additionally, the PTL may disrupt binding at the α-β interface by blocking or 
restricting binding at the GABA-binding site.  In fact, removal of the muscimol ligand and 
the flexible linker in MAB-0 enabled precise photocontrol of genetically engineered α1 
receptors suggesting delivery of a terminal phenol group to the GABA-binding site can 
disrupt channel gating.  Further modifications to PTL designs that provide functional 
groups that interact more favorably with the GABA-binding site have the potential to 
enhance the photoregulation effect of PTLs. 
 Hippocampal neurons expressing LiGABAAR enabled photoregulation of 
endogenous mIPSCs.  Subtype-specific LiGABAAR enable investigation into the role α1 
and α5 have in mediating phasic and tonic inhibition.  LiGABAAR photoregulation will 
provide a precise method to investigate the distribution of sub-type specific receptors 
and examine their functional role in leaning and memory.  Additionally LiGABAAR in 
intact hippocampal brain slices enabled photocontrol of action potential firing.  This result 
suggests that LiGABAAR can be utilized to exert light-switchable control on native 
receptors in the brain to investigate the role specific subtypes of GABAA receptors have 
in preventing epilepsy.     
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2.4  Methods 
2.4.1  Plasmid preparation  
2.4.1.1  Wild-type and mutant cDNAs 
The cDNAs of wild-type rat GABAAR α1 (in pGH19), β2 (in pGH19), and γ2S (in 
pUNIV) were obtained from Professor Cynthia Czajkowski (University of Wisconsin, 
USA).  The α5 wildtype subunit was obtained in vector pRK7 from Dr. Hartmut Luddens 
(University of Mainz, Germany).  The genes of α and β subunits were sub-cloned into 
vector pCDNA3.1(-) for expression in HEK293T cells and Xenopus oocytes.  Mutants 
α1(K70C) and α1(D123C) (in pGH19) were obtained from Professor Cynthia Czajkowski 
(University of Wisconsin-Madison).  Other cysteine mutants were prepared by site-
directed mutagenesis of the wild-type α1 and α5 clones in pCDNA3.1(-) using 
oligonucleotide primers under the following PCR profile: 1 cycle (95°C for 30s); 18 cycles 
(95°C for 50s, 60°C for 50s, 68°C for 9min); 1 cycle (68°C for 7min).  Mutations were 
confirmed by sequencing.  
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2.4.1.2  Adeno-associated virus construction of pAAV-hSyn-EGFP-2A-myc-
α1(T125C)  
 The construct is designed to express GFP and α1(T125C) in a 1:1 ratio using the 
2A protein sequence (GSGATNFSLLKQAGDVEENPGP) (Provost et al., 2007) and to 
restrict expression to neurons using the human synapsin promoter (Kugler et al., 2003).  
The vector also contains terminal repeats (TR) and woodchuck hepatitis post-
transcriptional regulatory element (WPRE) for packaging into the adeno-associated virus 
(AAV).  The human synapsin promoter was chosen because it allows powerful neuron-
specific expression of genes, and is easily delivered via an adenoviral vector.  Human 
synapsin 1 gene promoter confers highly neuron-specific long-term transgene 
expression from an adenoviral vector in the adult rat brain depending on the transduced 
area (Kugler et al., 2003).  The myc epitope (protein sequence EQKLISEEDL) was 
inserted into the α1(T125C) subunit as previously described (Connolly et al., 1996).   
The pAAV vector backbone was digested with NheI and HindIII and ligated with the 2A-
α1 and GFP-2A fragments.  The final construct was confirmed with sequencing. 
2.4.1.3   Preparation of Adeno Associated Virus (AAV) 
 AAV9 encoding GFP-2A-α1(T125C) produced by plasmid co-transfection into 
HEK293T cells as described previously (Choi et al., 2007).  After ultracentrifugation, the 
interphase between the 54 and 40% iodixanol fraction, and the lower three-quarters of 
the 40% iodixanol fraction, were extracted and diluted with an equal volume of 
phosphate- buffered saline (PBS) plus 0.001% Tween 20.  This fraction was then buffer 
exchanged and concentrated with Amicon Ultra-15 Centrifugal Filter Units to a final 
volume of ~100 µL.  The α1(T125C) AAV titered was 7.5 × 1012 vg/mL. 
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2.4.2  Cell culture, Mutant Expression and PTL treatment  
2.4.2.1  Xenopus oocytes 
 RNA was prepared with the mMessage mMachine T7 kit (Ambion, Austin, TX). 
Defolliculated Xenopus laevis oocytes were injected with 2.5–20 ng of mRNA in 50 nL 
H2O in a 1:1 ratio of α to β subunit RNA.  The injected oocytes were incubated at 18°C 
(in OR1 buffer) and subjected to two-electrode voltage-clamp recording 1–3 days after 
RNA injection.  The OR1 buffer comprised (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 
5 HEPES; pH 7.4.  For testing MAM-6 mediated photo-control of receptor activities, 
oocytes expressing cysteine substituted α1 or α5 mutants were incubated with 50 µM 
MAM-6 for 0.5–1.5 hr prior to recording. 
2.4.2.2  HEK293T cells 
 HEK293T cells were maintained in Dulbecco’s Minimum Essential Medium 
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) at 
37°C and 5% CO2.  Cells were plated at 18–24 × 103 cells/cm2 on poly-L-lysine coated 
coverslips and transfected by calcium phosphate precipitation.  A total of 0.9 µg DNA per 
coverslip (α1:β2:eGFP at 4:4:1 ratios) was added to the cells.  Recordings were 
performed 36 to 48 hours post-transfection.  For attaching PTL to the mutant receptors, 
cells were treated with dithiothreitol (DTT; 1 mM, 5 min), incubated in fresh external 
recording solution (5 min), and then treated with PTL (25 µM, 20 min, pH 8) at 37°C in 
the dark.  Whole-cell voltage-clamp recordings were performed thereafter. 
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2.4.2.3  Dissociated hippocampal neurons 
 Primary cultures of neonatal rat hippocampal neurons were performed using 
standard procedures, as previously described (Fortin et al., 2008).  Cells were grown in 
minimum essential medium (MEM) containing 5% FBS, 20 mM  glucose, B27 
(Invitrogen), 2 mM  glutamine and Mito+ Serum Extender (BD Biosciences).  
Transfection was performed via calcium phosphate precipitation 6–7 days after plating.  
Whole-cell electrophysiology recordings at 3 weeks after plating. 
2.4.2.4  Organotypic hippocampal slice cultures 
 Postnatal day 8 Sprague-Dawley rat pups were anaesthetized and decapitated.  
Hippocampi were removed and sliced into 350 µm thick sections using a tissue chopper 
(Stoelting, Wood Dale, IL).  Slices were maintained at 34°C on cell culture inserts 
(Milipore, Billerica, MA) in Neurobasal-A medium (Invitrogen) supplemented with 20% 
horse serum (Thermo Scientific, Waltham, MA), 0.03 units/ml insulin (Sigma, St. Louis, 
MO), 0.5 mM ascorbic acid (Sigma), 1X Gluta-Max (Invitrogen), 80units/ml penicillin, 
80µg/ml streptomycin (Invitrogen), and 25 mM HEPES.  One day after preparation, 
slices were injected with AAV9 encoding GFP-2A-α1(T125C).  The CA1 pyramidal cell 
body layer was injected at 3–7 sites/slice with 100nl of 1012-1013 vg/ml virus with a fine 
glass pipette.  5–14 days post-injection, slices were incubated for 2 min with 1 mM 
Tris(2- carboxyethyl)phosphine hydrochloride in artificial cerebrospinal fluid (ACSF) 
containing in mM: 126 NaCl, 2.5 KCl, 1.25 NaH2PO4, 10 Glucose, 1.3 MgCl2, 26 
NaHCO3 and 2.5 CaCl2 equilibrated with 95% O2/5% CO2, washed, and incubated with 
25 µM MAB-0 in ACSF for 30min at room temperature.  The PTL treated slices were 
subjected to whole- cell current-clamp recording. 
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2.4.3  Electrophysiology 
2.4.3.1  Two-electrode voltage-clamp of Xenopus oocytes 
 Single oocytes were placed in a 0.2-mL perfusion chamber and impaled with two 
glass microelectrodes (1–2.5MΩ resistance) filled with 3M KCl and voltage clamped with 
an OC-725C amplifier (Warner Instruments, Hamden, CT) in OR1 solution containing (in 
mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES; pH 7.4.  Oocytes were held at  
-80 mV.  Drug perfusion, data acquisition, and analysis were carried out with pClamp 
software and a Digidata 1200 interface (Molecular Devices, Sunnyvale, CA).  Oocytes 
were illuminated by a Lambda DG-4 (Sutter Instruments, Novato, CA) using 383 nm and 
497 nm filters. 
2.4.3.2  Whole-cell voltage-clamp of HEK293T cells 
 Recordings were performed using pipettes with 2.5–4 MΩ resistance.  Pipettes 
were pulled from filamented borosilicate pipettes (G150TF-3, Sutter Instruments).   
Extracellular solution contained (in mM): 140 NaCl, 5 KCl, 1 MgCl2, 10 HEPES, 2 CaCl2, 
10 glucose; pH 7.4.  Intracellular solution contained (in mM): 140 CsCl, 4 NaCl, 10 
HEPES, 2 MgCl2, 2 Mg-ATP, 10 EGTA; pH 7.2.  Cells were held at –70 mV.  Signals 
were amplified using a Patch Clamp PC-505A amplifier (Warner Instruments), digitized 
by a Digidata 1322A converter (Molecular Devices), and acquired with software Clampex 
10 (Molecular Devices).  Illumination for PTL photoisomerization was provided by a 
Lambda-LS xenon lamp (Sutter Instruments) with band pass filters (379 ± 17 nm and 
500 ± 8 nm). 
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2.4.3.3 Whole-cell voltage-clamp of dissociated hippocampal neurons 
 Voltage-clamp recordings were performed at room temperature using standard 
whole cell patch-clamp techniques.  Signals were amplified using a Patch Clamp PC-
505B amplifier (Warner Instruments), filtered at 2kHz, digitized at 10kHz using a Digidata 
1200 converter (Molecular Devices), and acquired using Clampex 8 (Molecular Devices). 
 To record spontaneous mIPSCs, cells were held at –60 mV.  The extracellular 
solution contained (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 HEPES, 10 
Glucose, 0.001 TTX (to block voltage-dependent Na+ channels), 0.025 DNQX (to block 
AMPA receptors), and 0.05 APV (to block NMDA receptors); pH 7.4.  The internal 
solution contained (in mM): 140 CsCl, 4 NaCl, 2 MgCl2, 10 HEPES, 10 EGTA, 2 Mg-
ATP; pH 7.4 
 To record spontaneous mEPSCs, cells were held at –70 mV.  The extracellular 
solution contained (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 HEPES, 10 
Glucose, 0.001 TTX, 0.02 bicuculline; pH 7.4.   The internal solution contained (in mM): 
8 NaCl, 135 K-gluconate, 4 MgCl2, 10 HEPES, 2 Mg-ATP, 1 EGTA; pH 7.4.  All 
miniature events were detected using the software MiniAnalysis (Synaptosoft, Decatur, 
GA) and were verified visually.  The search protocol threshold was set at fivefold the 
root-mean-square (RMS) noise level, which typically was 2–5 pA. 
 For recording voltage-gated currents, extracellular solution contained (in mM): 138 
NaCl, 1.5 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 HEPES, 10 Glucose, 0.02 bicuculine, 0.025 
DNQX, and 0.05 APV; pH 7.4.  The internal solution contained (in mM): 10 NaCl, 135 K-
gluconate, 2 MgCl2, 10 HEPES, 1 EGTA, 2 Mg-ATP; pH 7.4. Cells were held at –70 mV 
and stepped for 200ms to values between –100 and +40 mV, with increment steps of 10 
mV. 
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2.4.3.4  Whole-cell current-clamp recording of hippocampal slices 
 Slices were placed in a recording chamber mounted on an Olympus BX51WI 
microscope and perfused with ACSF at RT at 1–2 ml/min.  Whole-cell current clamp 
recordings were made from CA1 pyramidal cells with glass microelectrodes (R = 4–7 
MΩ) filled with internal solution containing (in mM): 116 K-gluconate, 20 HEPES, 6 KCl, 
2 NaCl, 0.5 EGTA, 4 ATP-Mg, 0.3 GTP-Na, ~ 7.2 pH, ~290mOsm.  A glass stimulating 
electrode was placed in stratum radiatum 300–500 µm away from the recorded cell. 
Synaptic responses were evoked by a 0.2 ms, 10–100 µA current pulse delivered via a 
stimulus isolation unit (AMPI, Jerusalem, Israel).  To record evoked IPSPs cells were 
depolarized to -45mV by somatic current injection.  Signals were amplified (Axopatch, 
Molecular Devices), digitized (Digidata, Molecular Devices) and recorded (pClamp, 
Molecular Devices) to computer.  Light was delivered through the microscope optical 
port by a Polychrome (Till Photonics, Munich, Germany) controlled by pClamp. 
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2.4.4  Molecular Modeling 
 Docking of trans- and cis-MAB-0 was carried out in the docking program GLIDE 
(Shrödinger Inc., Portland, OR) (Korpi et al., 2002), implemented in Maestro (Shrödinger 
Inc.).  A dimer of α1 and β2 subunits from a previously published homology model for 
GABAA receptor (α1β2γ2) was used (O'Mara et al., 2005).  Threonine residue 125 of the 
α1 subunit was replaced by a cysteine residue, and a receptor grid was created based 
on a dimmer with this α1 mutation.  Trans- and cis-MAB-0 were individually docked in 
the grid using the Standard Precision algorithm.  To mimic MAB-0 tethering, a positional 
constraint was applied during docking.  This constraint enforced at least one of the 
reactive carbons (of the maleimide) of MAB-0 to locate within 4.5 Ǻ from the cysteine 
side-chain carbon.  A maximum of 100 poses were listed.  The docking poses were 
further inspected visually to remove unreasonable results.  All of the docking poses for 
trans-MAB-0 insert the azobenzene moiety in the αβ interface.  The predominant 
docking mode of trans-MAB-0 is shown in Figure 2.4D top, in which the terminal phenol 
group of trans-MAB-0 reaches deeply into the GABA-binding site (surrounded by several 
aromatic residues represented in yellow).  The docking poses for cis-MAB-0 are fewer 
and more diversely oriented.  The majority of the cis poses place the terminal phenol 
group outside of the aromatic region of the GABA-binding site.  The bottom of Figure 2D 
bottom presents a docking pose of cis-MAB-0 that has a similarly positioned maleimide 
group to that of the trans pose, showing the change in the molecular shape and the 
accessibility of the phenol group when MAB-0 is switched from trans to cis conformation.   
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3 CHAPTER 3 
INCREASED HDAC6 EXPRESSION ALTERS TAU AND PP1 PROTEIN LEVELS 
3.1  Introduction 
 HDAC6 is a protein that has multiple roles in the cytosol.  This protein is a 
versatile multifunctional enzyme responsible for deacetylating key proteins involved in 
protein degradation pathways, cellular stress, and cytoskeletal dynamics (d'Ydewalle et 
al., 2012; Li et al., 2013; Parmigiani et al., 2008; Zhang et al., 2013).  The role of HDAC6 
in neurodegenerative disease is controversial.  It is unclear if the observed increases in 
HDAC6 protein levels in the AD brain are the result of a neuroprotective response to 
eliminate protein aggregates or an underlying causative agent in AD pathology and 
progression.  The experiments described here were devised to investigate the role of 
HDAC6 in AD tau pathology.  A heterologous mammalian cell culture system was 
utilized to assess the role of HDAC6 in a simplified system in which genes can be easily 
delivered and expressed.  The goal of this chapter is to determine if increased HDAC6 
protein levels lead to increased pathological tau accumulation and if disrupting an 
HDAC6-PP1 interaction decreases pathological tau.   
 Tau is a microtubule-associated protein (MAP), primarily expressed in neurons 
that promotes microtubule assembly and stabilization (Iqbal et al., 2005).  Tau plays a 
key role in regulating cytoskeletal microtubule dynamics, axonal transport and neurite 
outgrowth and all of these functions are modulated by site-specific phosphorylation 
(Johnson and Stoothoff, 2004).  Under normal physiological conditions, tau is in a 
constant equilibrium, on and off the microtubules (Ballatore et al., 2007; Dixit et al., 
2008).  The enzymatic activity of phosphatases and kinases control this equilibrium of 
microtubule-binding affinity by regulating the phosphorylation state of tau at serine and 
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threonine residues (Ballatore et al., 2007).  Tau phosphorylation is catalyzed by protein 
kinases and dephosphorylated by protein phosphatases.  An imbalance of protein kinase 
and protein phosphatase activity can lead to tau hyperphosphorylation.  One key 
phosphatase, protein phosphatase 1 (PP1) has been shown to interact with HDAC6 and 
this interaction is believed to disrupt the ability of PP1 to dephosphorylate tau leading to 
an increase in the accumulation of pathological hyperphosphorylated tau (Brush et al., 
2004; Ding et al., 2008).  
The human tau gene, located on chromosome 17, is alternatively spliced to 
generate six different isoforms.  The tau isoforms differ by having three repeat (3R) or 
four repeat (4R) microtubule-binding domains in the C-terminal and the presence or 
absence of exons 2 and 3 in the N-terminal (Buee et al., 2000; Johnson and Stoothoff, 
2004).  Healthy adult human brains contain approximately a 1:1 ratio of the 3R tau and 
4R tau isoforms.  Deviations from this 1:1 ratio are associated with neurodegenerative 
disease (Andorfer et al., 2003; Ballatore et al., 2007).  Since tau is primarily expressed in 
the brain, an established heterologous system that stably expresses tau was required for 
these experiments.   
Human embryonic kidney cells (HEK) stably expressing tau (HEK-tau) were 
chosen as the cell-line for these experiments because they stably express human tau 
isoforms with four microtubule binding repeats without exon 2 and 3 (Ding et al., 2008; 
Cho and Johnson, 2003).  These HEK-tau cells have been used to investigate tau 
phosphorylation in the presence of endogenous HDAC6 and disruption of the catalytic 
activity of HDAC6 by domain-selective small-molecule inhibitor tubacin or shRNA 
knockdown of HDAC6 in these cells was found to attenuate tau phosphorylation (Ding et 
al., 2008).  The experiments in this chapter were designed to assess if HDAC6 
overexpression altered tau pathology, and to examine PP1 levels in HEK-tau cells 
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expressing catalytically inactive HDAC6 or catalytically active HDAC6.  In order to target 
the catalytic domains of HDAC6 without altering protein folding or truncating the protein, 
established single-point mutations to render HDAC6 catalytically inactive were used 
(Brush et al., 2004; Ding et al., 2008; Haggarty et al., 2003).  
3.2 Results 
3.2.1  Overexpression HDAC6 alters tau protein levels 
 To assess if HDAC6 overexpression had an effect on the accumulation of 
pathological tau in a heterologous expression system, HEK-tau cells were transfected 
with human HDAC6.  Additionally single point mutations that rendered each of the 
catalytic domains of HDAC6 inactive, and a double mutant with both catalytic domains 
inactive were created.  Mutant HDAC6 constructs were created to assess if functional 
HDAC6 was responsible for increased tau phosphorylation and if disruption of an 
HDAC6-PP1 interaction attenuated tau phosphorylation.  Cells were lysed 36 hrs post-
transfection, total protein was separated by SDS-PAGE and then immunoblotted.  The 
monoclonal Tau-5 antibody was used to detect total tau (both phosphorylated and non-
phosphorylated forms of tau) (Tau-5, Invitrogen), a monoclonal FLAG antibody to verify 
HDAC6 expression (FLAG, Stratagene) and GAPDH as a loading control (GAPDH, 
SantaCruz).  HEK-tau cells overexpressing HDAC6 were found to have increased total 
tau protein levels of high-molecular weight compared to wild-type HEK-tau control cells 
(Figure 3.1).  HDAC6 overexpression in HEK-tau cells led to a  2.4 fold increase in total 
tau compared to wild-type HEK-tau control cells.  Unexpectedly, HEK-tau cells 
overexpressing catalytically inactive HDAC6 mutants: H216A, H611A, and double 
mutant H216AH611A all had increased total tau protein levels of high-molecular weight 
(Figure 3.1) suggesting increased accumulation of hyperphosphorylated tau 
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accumulation compared to wild-type HEK-tau control cells.  Mutant HDAC6 
overexpression in HEK-tau cells led to an total tau increase of 2.2 fold in H216A mutant 
expressing cells, a 2.0 fold increase in total tau in H611A mutant expressing cells, and a 
2.3 fold increase of total tau in catalytically inactive double mutant H216AH611A 
expressing cells compared to wild-type HEK-tau control cells.  
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Figure 3.1. Increased HDAC6 Expression Alters Tau Protein Levels  
 
A)  Schematic of FLAG-tagged HDAC6 constructs. 
B)  Proteins isolated from cell lysates of wild-type non-transfected HEK-tau control cells 
and HEK-tau cells transiently expressing HDAC6 constructs were separated by SDS-
PAGE and immunoblotted with mouse anti-FLAG (top-panel), mouse anti-Tau-5 (middle-
panel), and rabbit anti-GAPDH (bottom-panel).  Approximate molecular mass in kDa are 
shown next to representative blots.   
C)  Quantification of Tau-5 from wild-type non-transfected HEK-tau control cells and 
HEK-tau cells transiently expressing HDAC6 constructs plotted as mean ± S.E.M from at 
least 4 separate experiments are indicated.    
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3.2.2  Overexpression HDAC6 reduces PP1 protein levels 
 Next, HEK-tau cells overexpressing wild-type and mutant HDAC6 constructs 
were utilized to determine if the increase in hyperphosphorylated high-molecular weight 
tau was the result of altered PP1 protein levels or the enzymatic activity of PP1.  The 
monoclonal PP1 E-9 antibody was used to detect PP1 (PP1, SantaCruz) and GAPDH as 
a loading control (GAPDH, SantaCruz).  HEK-tau cells overexpressing HDAC6 had 
decreased PP1 protein levels compared to wild-type HEK-tau control cells (Figure 3.2).  
HDAC6 overexpression in HEK-tau cells led to a 1.55 fold decrease in PP1 protein 
levels compared to wild-type HEK-tau control cells.  Additionally, HEK-tau cells 
overexpressing catalytically inactive HDAC6 mutants: H216A, H611A, and double 
mutant H216AH611A all revealed decreased PP1 protein levels compared to wild-type 
HEK-tau cells (Figure 3.2).  Mutant HDAC6 overexpression in HEK-tau cells led to 
decreased PP1 levels of 1.19 fold in H216A mutant expressing cells, a 1.32 fold 
decrease in PP1 in H611A mutant expressing cells, and a 1.61 fold decrease in PP1 in 
catalytically inactive double mutant H216AH611A expressing cells compared to wild-type 
HEK-tau control cells.  These decreases in PP1 protein levels correlated with the 
increased accumulation of hyperphosphorylated high-molecular weight tau accumulation 
in these cells suggesting reduction in the amount of available PP1 to dephosphorylate 
tau leading to the pathological accumulation of tau in cells overexpressing both wild-type 
and catalytically inactive HDAC6.  Interestingly, overexpression of either catalytically 
inactive or wild-type HDAC6 led to decreased PP1 protein levels, revealing HDAC6 
catalytic activity was not necessary for altering PP1 homeostasis.   
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Figure 3.2. Increased HDAC6 Expression Alters PP1 Protein Levels  
 
A)  Schematic of FLAG-tagged HDAC6 constructs. 
B)  Proteins isolated from cell lysates of wild-type non-transfected HEK-tau control cells 
and HEK-tau cells transiently expressing HDAC6 constructs were separated by SDS-
PAGE and immunoblotted with mouse anti-PP1 (top-panel), and rabbit anti-GAPDH 
(bottom-panel).  Approximate molecular mass in kDa are shown next to representative 
blots.   
C)  Quantification of PP1 from wild-type non-transfected HEK-tau control cells and HEK-
tau cells transiently expressing HDAC6 constructs plotted as mean ± S.E.M from at least 
4 separate experiments are indicated.    
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3.2.3  Catalytically inactive HDAC6 does not deacetylate α-tubulin  
 The second catalytic domain of HDAC6 has been shown to be responsible for 
cytosolic deacetylase functions of HDAC6.  Therefore, to confirm that mutations to the 
second catalytic domain rendered HDAC6 catalytically inactive HEK-tau cells 
overexpressing wild-type and mutant HDAC6 constructs were used to assess levels of a 
well-known protein substrate, α-tubulin.  The monoclonal acetylated α-tubulin 6-11B-1 
antibody was used to detect levels of acetylated tubulin (Acetylated-tubulin, Sigma) and 
GAPDH as a loading control (GAPDH, SantaCruz).  As expected, the single-point 
mutation H611A of the second catalytic domain of HDAC6 rendered the enzyme inactive 
and thus unable to deacetylate α-tubulin (Figure 3.3).  This result confirmed that only 
mutations to the second catalytic domain rendered HDAC6 catalytically inactive.   
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Figure 3.3. Mutations to the Second Catalytic Domain of HDAC6 Render HDAC6 
Catalytically Inactive and Unable to Deacetylate Tubulin 
 
A)  Schematic of FLAG-tagged HDAC6 constructs. 
B)  Proteins isolated from cell lysates of wild-type non-transfected HEK-tau control cells 
and HEK-tau cells transiently expressing HDAC6 constructs were separated by SDS-
PAGE and immunoblotted with anti-Acetylated Tubulin (top-panel), and anti-GAPDH 
(bottom-panel).  Approximate molecular mass in kDa are shown next to representative 
blots.   
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3.3  Discussion 
 In the present study, overexpression of HDAC6 was identified as a potential 
underlying molecular factor altering both tau and PP1 protein levels.  The data presented 
here show that increased HDAC6 expression in a heterologous expression system leads 
to increased tau accumulation (Figure 3.1) that correlates with decreased PP1 (Figure 
3.2).  Further, recent publications have shown reduction or loss of HDAC6 alleviates 
abnormal tau accumulation and reduces cognitive deficits in a mouse model for 
Alzheimer’s disease (AD) (Cook et al., 2012; Govindarajan et al., 2013; Xiong et al., 
2013).  These data suggest that HDAC6 may be a novel target for potential therapeutic 
of AD.   
 To date, the available broad-spectrum HDAC inhibitors and HDAC6 specific 
inhibitors target the deacetylase enzymatic activity (Dallavalle et al., 2012; Haggarty et 
al., 2003; Inks et al., 2012; Xu et al., 2011).  Therefore experiments were designed to 
determine the effect of catalytically inactive HDAC6 on tau and PP1 protein levels.  
Inactivation of HDAC6 catalytic domain did not reverse the increase in pathological tau 
accumulation (Figure 3.1).  Further, HEK-tau cells expressing catalytically inactive 
HDAC6 resulted in reduced PP1 protein levels that were comparable to cells 
overexpressing functional HDAC6 thus revealing enzymatic activity of either catalytic 
domain of HDAC6 is not required for altering PP1 levels.  These data suggest that 
inhibitors that target the catalytic domain of HDAC6 will not be an effective therapeutic 
strategy in altering the accumulation pathological tau in AD.   
 Interestingly, Brush et al. reported that increased HDAC6 led to decreased 
phosphatase activity in a dose-dependent manner (Brush et al., 2004).  The second 
catalytic domain of HDAC6 has been shown to be responsible for interacting with the 
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catalytic domain of PP1 suggesting that HDAC6 deacetylates PP1 and regulates its 
enzymatic activity (Brush et al., 2004).  It was unexpected that PP1 levels were reduced 
in HEK-tau cells overexpressing both catalytically active and inactive HDAC6.  The data 
presented here suggest that an HDAC6-PP1 interaction at the second catalytic domain 
of HDAC6 is not responsible for the reduction in PP1 activity.  Previously, Ding et al. 
reported that by selectively inhibiting the enzymatic activity of the second catalytic 
domain of HDAC6 with tubacin or shRNA knockdown of HDAC6 decreased the amount 
of phosphorylated tau and suggested this was the result of the disruption of an HDAC6-
PP1 interaction (Ding et al., 2008).  The data reported here suggests that increased 
expression of HDAC6 leads to decreased PP1 protein levels and that this reduction in 
PP1 may lead to increased accumulation of pathological phosphorylated tau.  Both 
pathological tau accumulation and reduction in phosphatase levels are hallmarks of AD.  
 Acetylated tubulin is a marker of stable microtubules.  HDAC6 deacetylates α-
tubulin thus decreasing the level of acetylated tubulin and reducing the stability of 
microtubules.  Disruption of the microtubule network is a central pathological mechanism 
leading to neuronal dysfunction in neurons (Janke and Bulinski, 2011; Zhang et al., 
2013).  Interestingly, tau has been reported to be an inhibitor of the deacetylase function 
of HDAC6 (Perez et al., 2009).  Therefore experiments were designed to determine if 
HEK-tau cells that stably express tau inhibit the deacetylase function of HDAC6.  HEK-
tau cells expressing HDAC6 with a functional second catalytic domain (HDAC6 and 
H216A mutant HDAC6) had deacetylated tubulin levels confirming tau expression did 
not inhibit the deacetylase function of HDAC6 in these cells (Figure 3.3).  Additionally, 
HEK-tau cells expressing HDAC6 with a non-functional second catalytic domain (H611A 
mutant and H216AH611A) had acetylated tubulin levels comparable to wild-type control 
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HEK-tau cells (Figure 3.3).  As expected, targeting the α-tubulin deacetylase function of 
HDAC6 led to an increase in acetylated tubulin.   
 Analysis of the phosphorylation status of tau was not confirmed in HEK-tau cells 
stably expressing tau because HEK cells do not normally express tau therefore post-
translational modifications in these cells may not reflect the regulation of tau 
homeostasis in neurons.  Further, only tau isoforms with four microtubule-binding 
repeats without exon 2 and exon 3 are stably expressed in HEK-tau cells.  Normal adult 
human brain contains approximately a 1:1 ratio of the 3R tau and 4R tau isoforms and 
deviation from this ratio has been associated with neurodegenerative disease (Andorfer 
et al., 2003; Ballatore et al., 2007).  Further experiments to determine if increased 
HDAC6 expression alters tau phosphorylation in an endogenous system were required 
to address changes to tau pathology in neurons.   
3.4  Methods 
3.4.1  Cell culture 
3.4.1.1  HEK-tau cells 
 HEK-tau cells (Dr. Gail V. W. Johnson, University of Rochester Medical Center) 
were maintained in Dulbecco’s Minimum Essential Medium (DMEM) (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) at 37 °C with 5% CO2.  
Cells were transfected at 70% confluency in t-25 flask 24 hrs after plating with 
LipoD293 according to manufactures instructions (SignaGen).  
 63 
3.4.2  Constructs and site-directed mutagenesis of HDAC6  
 The cDNA of human HDAC6 was obtained from pcDNA3.1(+)HDAC6FLAG 
(Addgene plasmid #13823) and used to create catalytically inactive HDAC6.  Cysteine 
mutants were prepared by site-directed mutagenesis of wild-type HDAC6 using 
oligonucleotide primers to target the first catalytic domain (H216A), or the second 
catalytic domain (H611A) under the following PCR profile: 1 cycle (95 °C for 1 min); 18 
cycles (95 °C for 50 s, 68 °C for 50 s, 68 °C for 9.5 min); 1 cycle (68 °C for 7 min) 
(Agilent Technologies, QuickChangeII XL Site-directed Mutagenesis kit #200521).  The 
catalytically inactive double mutant (H216AH611A) was created by creating a single 
catalytic domain mutant and then targeting the remaining catalytic domain.  Mutations 
were confirmed by sequencing.  The H216A primer was 5'-cattaggcctcctggacatgccgccca 
gcac-3' and the H216A antisense primer was 3'-gtaatccggaggacctgtacggcgggtcgtg-5'.  
The H611A primer was 5'-gtcccccaggacacgccgcagagcaggatg-3' and the H611A 
antisense primer was 3'-cagggggtcctgtgcggcgtctcgtcctac-5'.   
3.4.3  Cell lysis, immunoblotting and analysis 
 HEK-tau cells were collected in lysis buffer (50 mM  Tris pH 7.4, 150 mM  NaCl, 
1% Triton X-100, 1 mM  EDTA, 1 mM  Na3VO4, 1 mM  NaF, and Protease Inhibitor 
Cocktail (Sigma P8340) containing 1.04 mM  AEBSF, 15 µM Pepstatin A, 14 µM E-64, 2 
µM Leupeptin, 4 µM Bestatin, 80 nM Aprotinin), incubated at 4 °C shaking for 30 minutes 
and centrifuged at 4 °C at 12,000 g for 10 minutes.  Protein concentrations were 
determined by bicinchoninic (BCA) assay (Pierce).  Total protein lysates (20 µg per 
sample) were separated by SDS-PAGE, transferred to nitrocellulose membrane with 
CAPS transfer buffer (10 mM  3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), 10 % 
Methanol, pH 11) and immunoblotted.  The membrane was blocked with 5 % bovine 
 64 
serum albumin (BSA) in 1X Tris Tween Buffered Saline (1X TTBS; 20 mM Tris, 137 mM 
NaCl, 0.1 % Tween-20, pH 7.6), and antibody incubations in 1 % BSA 1X TTBS and 
washes with 1 % BSA 1X TTBS.  The primary antibodies used in this study were: Mouse 
Anti-Tau5 (Invitrogen #AHB0042), Mouse Anti-FLAG (Stratagene #200471), Mouse Anti-
PP1 E-9 (Santa Cruz, sc-7482), Mouse Anti-Acetylated Tubulin 6-11B-1 (Sigma, T6793-
.2ML), Rabbit Anti-GAPDH (Sigma, G9545-25UL).  The secondary antibodies used in 
this study were: Goat Anti-Mouse IgG, HRP (Millipore, AP308P), Goat Anti-Rabbit IgG, 
HRP (Millipore, AP307P).  The membranes were incubated with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, 34080) and imaged on a G:box with cooled-CCD 
camera (Syngene).  HRP inactivation by excess hydrogen peroxide (blot incubation in 30 
% H202 for 30 min shaking at 37 °C) was used to enable multiple membrane probing of 
different species (rabbit vs. mouse) without the need for stripping blots.  Signal from 
GAPDH was used as a loading control for normalization.  Signal from wild-type non-
transfected HEK-tau cells were used as basis for the change in protein signal due to 
increased expression of HDAC6.  Band quantification was carried out using G:box gene 
tools analysis software.  All figures were prepared with GraphPad Prism ® version 6.     
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4 CHAPTER 4 
INCREASED HDAC6 EXPRESSION IS AN EARLY MARKER OF AD PROGRESSION 
4.1  Introduction 
 A major hurdle in studying AD is identifying novel targets that alter disease 
progression and pathology.  Once it was established that HDAC6 could be a potential 
underlying molecular factor altering tau pathology in a heterologuous expression system 
experiments were designed to investigate the neuropathological role of HDAC6 in AD in 
primary dissociated hippocampal neurons.  The experiments described in this chapter 
were performed to assess if increased HDAC6 protein levels in primary dissociated 
hippocampal neurons leads to the missorting of pathological phosphorylated tau to the 
soma and early synaptic dysfunction of these neurons.  Primary dissociated neurons are 
the simplest neuron culture system for evaluating changes in synaptic proteins and 
neuronal function.  The hippocampus was chosen because of its prominent role in 
learning and memory in the mammalian brain, the hippocampus is greatly decreased in 
size in AD due to neuron death, and HDAC6 protein levels are increased by 91% in the 
hippocampus of human post-mortem AD brains compared to age-matched control brains 
(Ding et al., 2008; Thies et al., 2013).   
 Another major hurdle in developing a neuron cell culture model system to study 
underlying molecular mechanisms in AD progression is that neurons are notoriously 
difficult to deliver genes of interest to using standard mammalian gene delivery 
techniques.  Neurons are post-mitotic and very sensitive to physical stress, and to 
changes in temperature, pH and osmolarity (Karra and Dahm, 2010).  Calcium 
phosphate (CaPO4) transfection results in low gene delivery (>5%), low expression, and 
few viable transfected cells where as lipid based transfection methods (Lipofectamine) 
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are toxic to neurons (Karra and Dahm, 2010).  Additionally, CaPO4 transfections have 
the highest gene delivery efficiency between day in vitro (DIV) 7 and DIV 10.  After this 
small-time frame, >1% of neurons are typically transfected.  Alternatively, nucleofection 
is a method similar to electroporation in that a series of high voltage pulses enable gene 
delivery.  Nucleofection is a proprietary technique requiring expensive reagents and 
equipment that have been modified for efficient (>60%) primary neuron gene delivery 
(Lonza Amaxa Nucleofector™).  Nucleofection requires very high concentrations of cells 
and the gene of interest to be delivered to neurons while in suspension before plating at 
DIV 0.  Methods that require gene delivery before DIV 16 have limited success in 
evaluating changes in synaptic proteins and neuronal function if the transfected neurons 
do not survive to DIV 18 to DIV 24 when they are synaptically active.   
 The only established technology to deliver genes of interest to neurons at any 
age with high efficiency is recombinant DNA technology via recombinant virus.  
Recombinant viruses are the method of choice for gene delivery in neurons because 
gene delivery efficiency has been reported to achieve 90 to 99% transduction, 
depending on the virus.  Recombinant viruses are not the first choice in gene delivery for 
neurons because they are a labor intensive, expensive, and demand safety precautions, 
typically requiring biosafety level 2+ practices.  For these experiments, recombinant 
adenovirus technology was chosen because the recombinant virus does not integrate 
into the genome eliminating the risk of insertional mutagenesis and ease of cloning and 
generating recombinant adenovirus (Karra and Dahm, 2010; Luo et al., 2007).    
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4.2  Results 
4.2.1  HDAC6 Gene Delivery in Neurons 
 Several methods were employed to deliver HDAC6 to primary neurons including 
CaPO4, and nucleofection.  Each of these methods were unsuccessful in transfecting 
neurons after DIV 10.  Each method resulted in less than 1% transfection efficiency and 
transfected neurons overexpressing HDAC6 were found to not be viable 4 days post-
transfection (data not shown).  A collaboration with Dr. Gregory Tew’s lab (UMASS 
Amherst, Polymer Science and Engineering) was initiated to evaluate novel polymers in 
mediating gene delivery in neurons.  These novel polymers had less than 1% 
transfection efficiency, and were unsuccessful in transfecting neurons past DIV 10 (data 
not shown).  In order to evaluate if increased HDAC6 protein levels in primary 
dissociated hippocampal neurons is an underlying molecular factor that leads to the 
missorting of pathological phosphorylated tau to the soma and early synaptic dysfunction 
of these neurons, recombinant HDAC6-adenovirus was generated and used to deliver 
FLAG-tagged HDAC6 to neurons.  Recombinant HDAC6_FLAG-Adenovirus (HFA) 
infection resulted in robust gene expression and >70% transfection efficiency in neurons 
at MOI 100.  Representative widefield images taken at 40X magnification of neurons 
infected at DIV 10 and fixed 36 hr post-transfection at DIV 12 show high transfection 
efficiency and expression (Figure 4.1B).  Fixed neuron cultures are autofluorescent and 
as expected, control neurons show non-specific autofluorescence (Figure 4.1A).  
Representative phase contrast images of wild-type control neurons vs. HFA infected 
neurons show healthy cultures (Figure 4.1C, Figure 4.1D).  These experiments 
established HFA infection as a reproducible and effective method for gene delivery of 
flag-tagged HDAC6 to primary hippocampal neurons.    
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Figure 4.1. Primary Hippocampal Neurons at DIV 12 
 
Scale bars, 100µM 
A) Autofluorescence of FLAG stained wild-type control neurons, DIV 12 at 40X. 
B) Distribution HDAC6 expression of FLAG stained HFA infected neurons, 36 hr post-
infection DIV 12 at 40X.  
C) Phase contrast image of control neurons from A, DIV 12 at 40X. 
D) Phase contrast image of HFA infected neurons from B, DIV 12 at 40X. 
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4.2.2  HDAC6 Overexpression Missorts Total Tau, Early and Late Pathological 
Tau to the Soma of Neurons 36 hr Post-Infection at DIV 12. 
 To assess if increased HDAC6 expression had an effect on tau localization, 
primary hippocampal neurons containing immature synapses were infected with HFA at 
an MOI of 100 and fixed 36 hrs post-infection at DIV 12.  Established tau markers were 
used to determine the effect of HDAC6 overexpression on the distribution of total tau, as 
well as early and late pathological tau.  The monoclonal Tau-5 antibody was used to 
detect total tau (both phosphorylated and non-phosphorylated forms of tau) (Tau-5, 
Invitrogen).  The pTau231 antibody was used to detect phosphorylation at Threonine 
231, a site important for regulating the ability of tau to bind microtubules and the 
pTau202 antibody specific to phosphorylation at Serine 202 was used to detect tau 
pathology in early and late stages of NFT formation (Andorfer et al., 2003). 
 In normal primary hippocampal neurons DIV 12 containing immature synapses, 
tau has distinct puncta staining (Figure 4.2A).  Within 36 hr of HDAC6 overexpression, 
neurons infected with HFA, total tau appears in the entire neuron, axon and 
somatodendritic compartment (Figure 4.2A).  HDAC6 overexpression led to a shift in the 
localization of total tau, a 1.7 fold increase of Tau-5 in soma of HDAC6 overexpressing 
neurons vs. control neurons.   
 To assess if the missorted tau was phosphorylated, a phospho-specific antibody 
(pTau231) that detects tau unbound from the microtubules was used.  Within 36 hr of 
HDAC6 overexpression, neurons infected with HFA, increased pTau231 immunostaining 
appears in the entire neuron, axon and somatodendritic compartment whereas control 
cells showed very little pTau231 immunostaining (Figure 4.3).  HDAC6 overexpression 
led to a  increase in phosphorylated tau and a 1.39 fold increase in pTau231 in soma of 
HDAC6 overexpressing neurons compared to control neurons.   
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 Next, a phospho-specific antibody (pTau202, phosphorylated Serine 202) that 
detects early and late pathological tau was used to determine if missorted tau was in fact 
NFTs.  Within 36 hr of HDAC6 overexpression, neurons infected with HFA, increased 
pTau202 immunostaining appears in the entire neuron, axon and somatodendritic 
compartment whereas control cells have distinct puncta staining restricted from the 
soma (Figure 4.4).  HDAC6 overexpression led to an increase in phosphorylated 
pathological tau, a 1.4 fold increase in the accumulation of pathological tau in the soma 
of HDAC6 overexpressing neurons compared to control neurons.  HDAC6 
overexpression in primary hippocampal neurons containing immature synapses led to 
the missorting of total tau, regulatory tau, and early and late pathological tau to the 
somatodendritic compartment.   
 
 71 
 
Figure 4.2. Increased Tau-5 in Soma of Neurons Overexpressing HDAC6 
 
A) Tau-5 distribution in wild-type control neurons (top) at DIV 12 and neurons 
overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 12.  Scale 
bars 100µM.   
B) Quantification of Tau-5 fluorescence intensity in soma plotted as mean ± S.E.M.  
Control, n = 143 cells (14 FOV); HDAC6 overexpressing, n = 109 cells (14 FOV).  **** P 
value < .0001.  FOV= fields of view 
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Figure 4.3. Increased pTau231 in Soma of Neurons Overexpressing HDAC6 
 
A) pTau231 distribution in wild-type control neurons (top) at DIV 12 and neurons 
overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 12.  Scale 
bars 100µM.   
B) Quantification of pTau231 fluorescence intensity in soma plotted as mean ± S.E.M.  
Control, n = 146 cells (10 FOV); HDAC6 overexpressing, n = 150 cells (15 FOV).  *** P 
value = 0.0003.  FOV= fields of view 
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Figure 4.4. Increased pTau202 in Soma of Neurons Overexpressing HDAC6 
 
A) Pathological pTau202 distribution in wild-type control neurons (top) at DIV 12 and 
neurons overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 12.  
Scale bars 100µM.   
B) Quantification of pTau202 fluorescence intensity in soma plotted as mean ± S.E.M.  
Control, n = 195 cells (16 FOV); HDAC6 overexpressing, n = 139 cells (21 FOV).  *** P 
value = 0.0003.  FOV = fields of view 
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4.2.3  Increase in Pathological pTau202 in Soma of Synaptically Active HDAC6 
Overexpressing Neurons. 
 To assess if HDAC6 overexpression had an effect on tau localization in 
synaptically active neurons, primary hippocampal neurons containing mature synapses 
were infected with HFA at an MOI of 100 at DIV 18 and fixed 36 hrs post-infection at DIV 
20 and 72 hrs post-infection at DIV 21.  Within 36 hr of HDAC6 overexpression, 
synaptically active neurons infected with HFA at DIV 20 have increased pTau202 in the 
entire neuron, axon and somatodendritic compartment whereas control cells have 
distinct tau puncta staining restricted from the soma (Figure 4.5A).  HDAC6 
overexpression 36 hrs post-infection led to a 1.22 fold increase in the accumulation of 
phosphorylated pathological tau in the soma of HDAC6 overexpressing neurons 
compared to control neurons at DIV 20 (Figure 4.5B).  By 72 hrs of HDAC6 
overexpression in synaptically active neurons at DIV 21 there is a distinct increase in the 
accumulation of phosphorylated pathological tau in the soma and puncta whereas 
control cells have tau puncta staining and tau restricted from the soma (Figure 4.6A).  
Interestingly, HDAC6 overexpression 72 hrs post-infection led to a  1.33 fold increase in 
the accumulation of phosphorylated pathological tau in the soma of HDAC6 
overexpressing neurons compared to control neurons at DIV 21 (Figure 4.6B).  
Comparison of pTau202 in the soma of control neurons at 36 hr vs. 72 hr was not 
significantly different.  There is an age-dependent 1.13 fold increase in the amount of 
pTau202 accumulating in the soma of HDAC6 overexpressing neurons at 36 hr at DIV 
20 vs. 72 hrs at DIV 21 and this increase is significant (P value = 0.0409).     
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Figure 4.5. Increased pTau202 in Soma of Synaptically Active Neurons 
Overexpressing HDAC6 36 hrs post-infection at DIV 20 
 
A) Pathological pTau202 distribution in wild-type control neurons (top) at DIV 20 and 
neurons overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 20.  
Max projection images of laser scanning confocal z-stacks, 63X oil-immersion, scale 
bars 50µM.   
B) Quantification of pTau202 fluorescence intensity in soma plotted as mean ± S.E.M.  
Control, n = 113 cells (33 FOV); HDAC6 overexpressing, n = 114 cells (29 FOV).  ** P 
value = 0.0019.   
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Figure 4.6. Increased pTau202 in Soma of Synaptically Active Neurons 
Overexpressing HDAC6 72 hrs post-infection at DIV 21 
 
A) Pathological pTau202 distribution in wild-type control neurons (top) at DIV 21 and 
neurons overexpressing HDAC6 (bottom) 72 hrs post-HFA MOI 100 infection at DIV 21.  
Max projection images of laser scanning confocal z-stacks, 63X oil-immersion, scale 
bars 50µM.   
B) Quantification of pTau202 fluorescence intensity in soma plotted as mean ± S.E.M.  
Control, n = 146 cells (40 FOV); HDAC6 overexpressing, n = 140 cells (43 FOV).  **** P 
value < 0.0001.   
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4.2.4  Decreased pTau202 Puncta in Synaptically Active HDAC6 Overexpressing 
Neurons at DIV 20 
 To assess if HDAC6 overexpression had an effect on the size or number of tau 
puncta in synaptically active neurons, primary hippocampal neurons containing mature 
synapses were infected with HFA at an MOI of 100 at DIV 18 and fixed 36 hrs post-
infection at DIV 20.  Puncta size ranges are typically characterized into three size ranges 
based on their role in synaptic plasticity: 0.2 – 0.5µM2, 0.5 – 1µM2, and 1 - 2µM2.  
Analysis of the average pTau202 puncta overall size for control compared to HDAC6 
overexpressing neurons at 36 hrs post-infection at DIV 20 was not significant (control = 
0.612 ± 0.003, n=15,876; HDAC6 overexpressing = 0.621 ± 0.003, n=12,312).  At 36 hr 
post-infection, neurons overexpressing HDAC6 at DIV 20 had an overall decrease in 
total number of puncta at each size range compared to wild-type control neurons at DIV 
20 (Figure 4.7).  Although this reduction in average number of pTau202 puncta per FOV 
in each size range was not significant, the decrease in total number of puncta was 
22.45% (total pTau202 puncta detected 0.2 to 2µM2: control = 15,876; HDAC6 
overexpressing = 12,312).  Comparison of images of control neurons compared to 
HDAC6 overexpressing neurons at 36 hr post-infection at DIV 20 show an increased 
overall fluorescence intensity of pTau202 puncta (Figure 4.5A) but the size of pTau202 
puncta was decreased at each size range, which led to investigation of the average 
fluorescence intensity of the detected puncta at each size range.  Indeed, at each size 
range the fluorescence intensity of pTau202 puncta was significantly increased in 
neurons overexpressing HDAC6 at 36 hr post-infection at DIV 20 vs. control neurons 
(Figure 4.8).  
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Figure 4.7. Average Number of pTau202 Puncta per FOV at DIV 20 
 
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20.  HDAC6 
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29 
FOV). The total number of pTau202 puncta detected (0.2 to 2µM2) from 113 control 
cells= 15,876; 114 HDAC6 overexpressing cells = 12,312.      
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Figure 4.8. Average Fluorescence Intensity of pTau202 puncta in DIV 20 neurons 
 
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20.  HDAC6 
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29 
FOV). Data plotted as mean ± SEM, n = total puncta detected.  At 0.2 to 0.5µM2: Control 
= 2,536 ± 2.941, n=8,426; HDAC6 = 2,574 ± 3.750, n=6,521.  At 0.5 to 1µM2: Control = 
2,732 ± 4.386, n=4,873; HDAC6 = 2,768 ± 5.533, n=3,664.  At 1 to 2µM2: Control = 
2,844 ± 6.059, n=2,577; HDAC6 = 2,867 ± 6.886, n=2,127.    
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4.2.5  Decreased pTau202 Puncta in Synaptically Active HDAC6 Overexpressing 
Neurons at DIV 21 
 Next, to assess if HDAC6 overexpression had an effect on the size or number of 
tau puncta in synaptically active neurons, primary hippocampal neurons containing 
mature synapses were infected with HFA at an MOI of 100 at DIV 18 and fixed 72 hrs 
post-infection at DIV 21.  Analysis of the average size of pTau202 puncta for control vs. 
HDAC6 overexpressing neurons at 72 hrs post-infection at DIV 21 was significant 
(control = 0.596 ± 0.002, n=31,156; HDAC6 overexpressing = 0.607 ± 0.003, n=16,884).  
At 72 hr post-infection, neurons overexpressing HDAC6 at DIV 21 had a decrease in 
total number of puncta at each size range compared to wild-type control neurons at DIV 
21 (Figure 4.9).  The decrease in total number of pTau202 puncta was 45.8% (total 
pTau202 puncta detected 0.2 to 2µM2: control = 31,156; HDAC6 overexpressing = 
16,884).  Images of control neurons compared to HDAC6 overexpressing neurons at 72 
hr post-infection at DIV 21 appeared to have increased overall fluorescence intensity of 
pTau202 puncta (Figure 4.6A) but the actual size of pTau202 puncta was decreased at 
each size range, which led to investigation of the average fluorescence intensity of the 
detected puncta at each size range.  Indeed, at each size range the fluorescence 
intensity of pTau202 puncta was increased and statistically significant in neurons 
overexpressing HDAC6 at 72 hr post-infection at DIV 21 compared to control neurons 
(Figure 4.10). 
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Figure 4.9. Average Number of pTau202 Puncta per FOV at DIV 21  
 
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21.  HDAC6 
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43 
FOV). The number of total pTau202 puncta detected (0.2 to 2µM2) from 146 control cells 
= 31,156; 140 HDAC6 overexpressing cells = 16,884. Data plotted as mean ± SEM, n = 
total FOV.  At 0.2 to 0.5µM2: Control = 432.6 ± 34.83, n=40; HDAC6 = 212.4 ± 20.69, 
n=43.  At 0.5 to 1µM2: Control = 225.7 ± 19.55, n=40; HDAC6 = 116.9 ± 11.85, n=43.  At 
1 to 2µM2: Control = 120.6 ± 11.62, n=40; HDAC6 = 63.12 ± 7.273, n=43.    
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Figure 4.10. Average Fluorescence Intensity of pTau202 puncta in DIV 21 neurons 
 
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21 and HDAC6 
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43 
FOV). Data plotted as mean ± SEM, n = total puncta detected.  At 0.2 to 0.5µM2: Control 
= 2,570 ± 2.132, n=17,304; HDAC6 = 2,600 ± 3.356, n=9,128.  At 0.5 to 1µM2: Control = 
2,744 ± 3.158, n=9,029; HDAC6 = 2,796 ± 4.837, n=5,028.  At 1 to 2µM2: Control = 
2,822 ± 4.135, n=4,823; HDAC6 = 2,875 ± 6.295, n=2,714.   
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4.2.6  Decreased PSD-95 Puncta in Synaptically Active Neurons Overexpressing 
HDAC6  
 To assess if HDAC6 overexpression had an effect on the size or number of PSD-
95 puncta in synaptically active neurons, primary hippocampal neurons containing 
mature synapses were infected with HFA at an MOI of 100 at DIV 18 and fixed at 36 hr 
post-infection at DIV 20 and 72 hrs post-infection at DIV 21.  PSD-95 is an important 
scaffolding protein that has a functional role in maintaining molecular organization of 
postsynaptic dendritic spines and synaptic plasticity.  Significant reduction of PSD-95 is 
an indicator of synaptic dysfunction in post-mortem AD brains (Proctor et al., 2011) 
therefore PSD-95 was used as a marker for synaptic dysfunction in neurons 
overexpressing HDAC6. 
 Representative images of PSD-95 puncta from DIV 20 for control and HDAC6 
overexpressing at 36 hr post-infection neurons are shown in Figure 4.11A.  
Quantification of PSD-95 puncta from DIV 20 for control compared to HDAC6 
overexpressing at 36 hr post-infection revealed neurons overexpressing HDAC6 at DIV 
20 had significant decreases in total number of puncta at each size range compared to 
wild-type control neurons at DIV 20 (Figure 4.11).  Within 36 hrs of HDAC6 
overexpression the average PSD-95 puncta size (0.2 to 2µM2) from DIV 20 neurons 
decreased by 1.15 fold compared to wild-type control neurons (Figure 4.12).  The 
percent decrease of the total number of PSD-95 puncta was 77.9% (total pTau202 
puncta detected 0.2 to 2µM2: control = 2,697; HDAC6 overexpressing = 596).    
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Figure 4.11. Average Number of PSD-95 Puncta per FOV at DIV 20 
 
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20.  HDAC6 
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29 
FOV).  
A)  Representative PSD-95 images showing puncta distribution in control neurons (top) 
at DIV 20 and neurons overexpressing HDAC6 infected with HFA MOI 100 (bottom) and 
fixed at 36 hrs post-infection at DIV 20. Max projection images of laser scanning 
confocal z-stacks, 63X oil-immersion, scale bars 50µM.   
B)  Data plotted as mean ± SEM, n = total FOV.  At 0.2 to 0.5µM2: Control = 55.21 ± 
8.285, n=33; HDAC6 = 15.97 ± 3.814, n=29.  At 0.5 to 1µM2: Control = 20.33 ± 3.624, 
n=33; HDAC6 = 3.586 ± 0.9023, n=29.  At 1 to 2µM2: Control = 6.152 ± 1.501, n=33; 
HDAC6 = 1.000 ± 0.5012, n=29. The total number pTau202 puncta detected (0.2 to 
2µM2) from 113 control cells= 2,697; 114 HDAC6 overexpressing cells = 596.      
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Figure 4.12. Average Size of PSD-95 Puncta from DIV 20 Neurons 
 
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20.  HDAC6 
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29 
FOV).  
Data plotted as mean ± SEM, n = total number puncta: Control = 0.483 ± 0.006, 
n=2,697; HDAC6 overexpressing = 0.418 ± 0.011, n=596.  
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 Next, analysis of the effect of HDAC6 overexpression 72 hrs post-infection of DIV 
21 on PSD-95 puncta number and size from primary hippocampal neurons with mature 
synapses was compared to wild-type control DIV 21 neurons.  Representative images of 
PSD-95 puncta from DIV 21 for control vs. HDAC6 overexpressing at 72 hr post-
infection neurons are shown in Figure 4.13A.  Quantification of PSD-95 puncta from DIV 
21 for control and HDAC6 overexpressing at 72 hr post-infection revealed neurons 
overexpressing HDAC6 at DIV 21 had significant decreases in total number of puncta at 
both 0.2 – 0.5µM2 and 0.5 – 1µM2  ranges compared to wild-type control neurons at DIV 
21 (Figure 4.13B).  The percent decrease of the total number of PSD-95 puncta was 
53.44% (total pTau202 puncta detected 0.2 to 2µM2: control = 3,052; HDAC6 
overexpressing = 1,421).  Analysis of the average PSD-95 puncta size (0.2 to 2µM2) for 
HDAC6 overexpressing neurons at 72 hrs post-infection at DIV 21 increased slightly by 
1.08 fold compared to wild-type control neurons DIV 21 (Figure 4.14).   
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Figure 4.13. Average Number of PSD-95 Puncta per FOV at DIV 21 
 
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21.  HDAC6 
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43 
FOV). A)  Representative PSD-95 images showing puncta distribution in control neurons 
(top) at DIV 21 and neurons overexpressing HDAC6 infected with HFA MOI 100 
(bottom) and fixed at 72 hrs post-infection at DIV 21.  Max projection images of laser 
scanning confocal z-stacks, 63X oil-immersion, scale bars 50µM.   
B)  Data plotted as mean ± SEM, n = total FOV.  At 0.2 to 0.5µM2: Control = 53.83 ± 
9.032, n=40; HDAC6 = 21.72 ± 4.217, n=43.  At 0.5 to 1µM2: Control = 17.28 ± 3.175, 
n=40; HDAC6 = 8.302 ± 2.376, n=43.  At 1 to 2µM2: Control = 5.200 ± 1.133, n=40; 
HDAC6 = 3.023 ± 0.973, n=43. The total number pTau202 puncta detected (0.2 to 2µM2) 
from 146 control cells= 3,052; 140 HDAC6 overexpressing cells = 1,421.      
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Figure 4.14. Average Size of PSD-95 Puncta from DIV 21 Neurons 
 
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21.  HDAC6 
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43 
FOV). Data plotted as mean ± SEM, n = total number puncta: Control = 0.465 ± 0.005, 
n=3,052; HDAC6 overexpressing = 0.500 ± 0.009, n=1,421.  
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4.3  Discussion 
 Tau homeostasis is regulated by a series of post-translational modifications 
including phosphorylation, acetylation, glycosylation, etc (Spires-Jones et al., 2009).  It is 
well established that tau is a microtubule-associated protein primarily expressed in 
neurons and localized to the axon (Ballatore et al., 2007; Iqbal et al., 2005; Johnson and 
Stoothoff, 2004).  This study focused solely on changes in tau phosphorylation because 
of its implicated role in tau dysregulation, AD pathology, and disease progression.  
 Phosphorylation of tau is a post-translational modification that regulates the 
affinity of tau for microtubules.  In healthy neurons, the phosphorylation of tau is tightly 
regulated enabling tau to bind to microtubules stabilizing them whereas and 
phosphorylated tau with reduced affinity for microtubules enables axonal transport.  Site-
specific phosphorylation of tau enables tau to regulate cytoskeletal microtubule 
dynamics, axonal transport and neurite outgrowth (Johnson and Stoothoff, 2004).  
Specifically, phosphorylation of tau at threonine 231 has been observed to reduce the 
affinity of tau for microtubules (Cho and Johnson, 2003; Cho and Johnson, 2004; 
Goedert et al., 1994).  However, phosphorylation alone is not an indicator of AD tau 
pathology as healthy fetal and adult brains have phosphorylated tau (Buee et al., 2000). 
  Abnormal hyperphosphorylation that leads to tau aggregation and missorting is 
an indicator of tau pathology.  In degenerating neurons, hyperphosphorylation of tau 
leads to intracellular tau aggregation and the formation of neurofibrillary tangles (NFTs) 
containing both hyperphosphorylated and non-phosphorylated tau isoforms that are 
missorted to the somatodendritic compartment.  Interestingly, the largest tau isoform has 
seventy-nine threonine and serine residues that are potential phosphorylation sites 
(Buee et al., 2000) of which more than half have been found to be phosphorylated and 
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implicated in tau pathology in AD brains (Hanger et al., 2007).  Tau dysregulation, 
mislocalization of tau to soma and dendritic spines, the role of tau in dendritic spines, 
and tau dysfunction are implicated in AD pathology and progression (Haass and 
Mandelkow, 2010; Hoover et al., 2010; Ittner et al., 2010).  Both missorting of tau and 
synapse loss is an early change in AD brains that precedes Aβ accumulation, NFTs and 
cognitive dysfunction.   
 HDAC6 recombinant adenovirus was developed to deliver HDAC6 to primary 
dissociated hippocampal neurons isolated from post-natal rat brains for the investigation 
of the neuroprotective vs. neuropatholgoical role of increased HDAC6 protein levels in 
AD pathology and synaptic dysfunction.  Early changes that mediate tau dysregulation 
and the accumulation and missorting of hyperphosphorylated pathological tau have 
remained elusive, therefore initial experiments were designed to investigate if HDAC6 
overexpression led to any change in tau pathology including phosphorylation and 
missorting to the somatodendritic compartment in developing neurons.  The data 
presented here indicates that HDAC6 as an underlying molecular factor in AD and a key 
player in mediating the missorting of pathological tau and synaptic dysfunction.   
 HDAC6_FLAG-Adenovirus enabled reproducible, efficient HDAC6 gene delivery 
and subsequent overexpression in primary dissociated hippocampal neurons (Figure 
4.1).  Increased expression of HDAC6 resulted in AD tau pathology and synaptic 
dysfunction.  Increased HDAC6 was neuropathological in primary hippocampal neurons.  
HDAC6 overexpression missorted total tau to the soma of developing neurons (Figure 
4.2).  Since NFTs are composed of aggregates of phosphorylated and non-
phosphorylated forms of tau that missort to the soma of neurons markers to determine 
the phosphorylation state of missorted tau was used.  The phospho-specific antibody 
pTau231 detects tau with disrupted affinity for microtubules.  Wild-type control neurons 
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had minimal staining of pTau231 suggesting these neurons have stable microtubules 
(Figure 4.3).  Neurons overexpressing HDAC6 had distinct pTau231 staining of the 
entire neuron, axon and somatodendritic compartment suggesting a potentially 
destabilized microtubule network.  Disruption of the microtubule network is a central 
mechanism leading to neuronal dysfunction (Zhang et al., 2013).   
 Further, the pTau202 antibody that detects phosphorylated Serine 202 indicative 
of NFTs (aggregated hyperphosphorylated tau) was used to confirm early and late tau 
pathology.  Surprisingly, wild-type control neurons stained with pTau202 had puncta 
staining restricted from the soma suggesting phosphorylation of Serine 202 may have a 
functional role in mediating synaptic organization in healthy developing neurons (Figure 
4.4).  Neurons overexpressing HDAC6 show elevated pTau202 staining in the soma, 
indicating pathological tau accumulation in the soma (Figure 4.4).  Dysfunction of 
hyperphosphorylated tau is well-studied and implicated in microtubule destabilization, 
aggregation, missorting of tau to the soma and dendritic spines, and synaptic 
dysfunction in neurons.   
 Experiments in synaptically active neurons were performed to investigate the 
impact of HDAC6 overexpression on tau pathology and synaptic dysfunction.  Tau 
mislocalization in dendritic spines has been implicated in disrupting glutamate receptor 
(AMPA and NMDA receptors) trafficking and hence synaptic function (Hoover et al., 
2010).  The phosphospecific antibody pTau202 was used to recognize aggregated 
phosphorylated tau.  Synaptically active neurons overexpressing HDAC6 show 
increased pTau202 staining in the soma, indicating pathological tau accumulation in the 
soma compared to wild-type control neurons (Figure 4.5, Figure 4.6).  Synaptically 
active, wild-type control neurons showed puncta staining of phosphorylated tau 
restricted from the soma suggesting phosphorylation of Serine 202 may have a 
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functional role in mediating synaptic organization in healthy synaptically active neurons 
(Figure 4.5, Figure 4.6).  Additionally, synaptically active neurons overexpressing 
HDAC6 had decreased total number of phosphorylated tau puncta suggesting changes 
in synaptic organization in these neurons (Figure 4.7, Figure 4.9).   
 Missorting of tau to soma in neurons correlates with the degeneration of 
synapses (Thies and Mandelkow, 2007), therefore I investigated changes in the size, 
number and fluorescence intensity of tau puncta to determine potential synaptic 
regulation mediated by HDAC6 expression.  Compared to age-matched wild-type control 
neurons, neurons overexpressing HDAC6 had decreased tau puncta.  Interestingly, the 
fluorescence intensity of size-matched tau puncta was increased in neurons 
overexpressing HDAC6 indicating increases in the amount of phosphorylated tau protein 
in puncta of the same size compared to wild-type neurons.  This change in fluorescence 
intensity of phosphorylated tau suggests increased pathological tau in puncta leads to 
disruption of synaptic puncta organization and tau missorting in neurons overexpressing 
HDAC6.   
 The shift in tau homeostasis that mediates functional tau and pathological tau is 
regulated by a series of post-translational modifications.  Recently, a number of studies 
have implicated acetylated tau as contributing to tau dysfunction, aggregation and 
accumulation by prevention of its degradation in AD (Cohen et al., 2011; Irwin et al., 
2012; Min et al., 2010).  It is likely that a combination of post-translational modifications 
(i.e. phosphorylation, acetylation) lead to hyperphosphorylated tau and accumulation of 
aggregated tau that is missorted to soma of neurons. 
 Altered neuronal communication at the synapse and a decreased number of 
postsynaptic receptors correlates with changes in synaptic strength and plasticity (Bingol 
et al 2011).  Experiments were designed to investigate any changes in the synaptic 
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organization of an important scaffolding protein, postsynaptic density protein 95 (PSD-
95) mediated by HDAC6 overexpression.  PSD-95 is the most-abundant scaffolding 
protein in postsynaptic densities, and is one of the most stable proteins in dendritic 
spines (Chen et al., 2011; Kasai et al., 2010).  PSD-95 plays a functional role in 
maintaining molecular organization of excitatory dendritic spines and plays a pivotal role 
in LTD (Bhattacharyya et al., 2009; Chen et al., 2011).  Interestingly, synaptically active 
neurons overexpressing HDAC6 had significant decreases in the total amount of PSD-
95 puncta compared to wild-type control neurons (Figure 4.11, Figure 4.13).  These 
reductions in the total number of PSD-95 puncta in neurons overexpressing HDAC6 
suggest HDAC6 has a neuropathological role in disrupting the molecular organization of 
dendritic spines and impairing synaptic neurotransmission.  Additionally, loss of 
postsynaptic scaffolding protein PSD is believed to contribute to AMPA receptor 
dependent LTP deficits in AD (Proctor et al., 2011).  The size of synaptic puncta has 
been reported to correlate with changes synaptic neurotransmission and LTD and LTP.  
The average size of PSD-95 puncta was reduced at 36 hr post-infection in neurons 
overexpressing HDAC6 at DIV 20 (Figure 4.12), yet at neurons overexpressing HDAC6 
for 72 hrs at DIV 21 the average size of PSD-95 puncta was increased (Figure 4.13).  
The PSD-95 data of neurons overexpressing HDAC6 for 36 hrs and 72 hrs compared to 
age-matched wild-type control neurons suggests a potential compensatory mechanism 
altering the total number of PSD-95 puncta and average size of PSD-95 when synaptic 
communication is disrupted by tau missorting and changes to PSD-95 during disease 
progression. 
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4.4  Methods  
4.4.1  Cell Culture 
4.4.1.1  HEK293T cells 
 HEK293T cells were maintained in Dulbecco’s Minimum Essential Medium 
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) at 
37°C and 5% CO2.  Cells were plated at 70% confluency in T75-flask and transfected 24 
hrs after plating with LipoD293 according to manufactures instructions (SignaGen).  
4.4.1.2  HeLa cells 
 HeLa cells were maintained in Eagle's Minimum Essential Medium (EMEM) 
(ATCC Catalog #30-2003) supplemented with 10% FBS at 37°C and 5% CO2.  For 
Adenoviral titer, cells were plated at 85% confluency.   
4.4.1.3  Dissociated hippocampal neurons 
 All experiments involving rats were performed in accordance with local 
institutional and government regulation for animal welfare.  Primary cultures of post-natal 
rat hippocampal neurons isolated from Sprague-Dawley rat pups (Charles Rivers 
Laboratories) were performed using standard procedures.  Neurons were plated at 62–
75 × 103 cells/cm2 on poly-L-lysine coated glass coverslips and were grown in minimum 
essential medium (MEM) containing 5% FBS, 25 mM  glucose, B27 (Invitrogen), 2 mM  
glutamine and Mito+ Serum Extender (BD Biosciences).  Neurons were maintained in 
culture with ½ media changes every three days.  Gene delivery was performed by 
HDAC6_FLAG-Adenovirus at a 100-fold multiplicity of infection (MOI).    
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4.4.2  Generation of HDAC6 recombinant adenovirus 
 Recombinant adenovirus was generated following the AdEasy method for 
generation and production similarly to previously described (Luo et al., 2007).  Briefly, 
the following plasmids were used pcDNA3.1(+)HDAC6FLAG (Addgene plasmid 
#13823),  pShuttleCMV (Addgene plasmid #16403), pAdEasy-1 (Addgene plasmid 
#16400).  The cDNA of human HDAC6 with an engineered c-terminal FLAG tag was 
PCR amplified from pcDNA3.1(+)HDAC6FLAG subcloned into pShuttleCMV using 5’ 
BglII and 3’ HindIII sites. The resulting pShuttleCMV_HDAC6FLAG construct was 
linearized with PmeI and co-transformed with pAdEasy-1 into Escherichia coli BJ5183 
cells (Addgene strain # 16398) for homologous recombination.  Recombinant adenoviral 
plasmids were verified by PacI digestion.  The recombinant adenoviral plasmid isolated 
from verified recombinant clones was transformed into recombination-defective 
Novablue strain.  The recombinant adenoviral plasmid was then digested with PacI and 
used to transfect HEK293T cells (which contain E1 genes for adenoviral packaging) 
using LipoD293.  Media was changed 16 hours post-transfection following BSL-2+ 
practices, and cells were maintained at 37°C and 5% CO2 for 42 days until the primary 
HDAC6_FLAG-adenoviral stock was harvested by freeze-thaw.  
4.4.3  Recombinant Adenovirus titer using immunocytochemistry 
 HeLa cells were infected with crude HDAC6_FLAG-Adenoviral stocks titrated 
from 10-5 to 10-16 in biological replicates of 4.  Cells were fixed with 4% 
paraformaldehyde 24 hrs post-infection.  Fixed cells were permeabilized with 0.1% 
TritonX-100.  Cells were blocked with 5% goat serum and immunostained with a 1° 
antibody that detects Adenovirus type 5 Hexon protein (DSHB catalog # TC31-9C12.C9) 
followed by 2° Goat Anti-mouse IgG Dylight 488 (Pierce #35502).  Widefield fluorescent 
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images were acquired and the average number of infected cells per area was calculated.  
The equation used to calculate viral titer was {(average number of infected cells/fields of 
view)*(total number of fields of view possible/well)*(dilution factor)}/{(virus volume added 
per well)}.  This equation calculated the number of viral infection units per mL in the 
crude viral stock.  This method for adenovirus viral titer was designed with adenovirus 
expert Dr. Gary Ketner at John Hopkins University School of Medicine by adapting a 
protocol from his laboratory.  
 
4.4.4 Neuron Immunocytochemistry 
 Neurons were fixed with 4% paraformaldehyde at the appropriate time-point.  
Fixed cells were permeabilized with 0.1% TritonX-100.  Cells were blocked with 5% goat 
serum and immunostained with the appropriate primary and secondary antibodies.  The 
primary antibodies used were Mouse Anti-PSD-95 (Millipore #MAB1596), Mouse Anti-
Tau5 (Invitrogen #AHB0042), Mouse Anti-FLAG (Stratagene #200471), Rabbit Anti-
pTau202 (Anaspec #28017-025), Rabbit Anti-pTau231 (Anaspec #55313-025), Chicken 
Anti-FLAG (AFLAG-5).  The secondary antibodies used were Goat Anti-mouse IgG 
Dylight 488 (Pierce #35502), Goat Anti-rabbit IgG Dylight 549 (Pierce #35557), Goat 
Anti-Chicken Alexa Fluor 633 (Invitrogen #A21103).  Images were acquired using a Zeis 
Laser Scanning 510 Meta confocal microscope at 63X (Plan-Apochromat 63X/1.4NA) 
oil-immersion using the appropriate lasers (488nm, 543nm, 633nm) and filters.  Four 
channel (488nm, 549nm, 633nm, DIC) Z-stack 12 bit (1024 X 1024) images were 
acquired as 26 stacks at .1µM intervals.  Images were acquired with settings to avoid 
pixel saturation and these settings were the same for all image acquisition for control 
and HDAC6 overexpressing cells.  
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4.4.4  Neuron Image analysis 
4.4.4.1 FLAG Analysis 
 Images of at least 10 fields of view were taken for both control and HFA infected 
neurons.  Using ImageJ software (NIH), z-stacks images split into 4 channels and MAX-
intensity projection images of the appropriate channel were used.  All neuron somas in 
these images were chosen as region of interest (ROI), and three background areas were 
chosen as background ROI for each image.  The background ROI were averaged and 
subtracted from the average FLAG fluorescence of the soma ROI.  Neurons were 
identified as HDAC6 overexpressing neurons or positive infected cells if they had FLAG 
fluorescence above the average control FLAG autofluorescence.   
4.4.4.2  Tau Soma Analysis 
 Images of at least 10 fields of view were taken for both control and HFA infected 
neurons.  Using ImageJ software (NIH), z-stacks images were split into 4 channels and 
MAX-intensity projection images of the appropriate channel were used.  All neuron 
somas in these images were chosen as a ROI, and three background areas were 
chosen as background ROI for each image.  The background ROI were averaged and 
subtracted from the average Tau fluorescence of the soma ROI.  All figures were 
prepared with GraphPad Prism ® version 6. 
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4.4.4.3  Tau puncta analysis 
 Images of at least 10 fields of view were taken for both control and HFA infected 
neurons.  Using ImageJ software (NIH), z-stacks images were split into 4 channels and 
MAX-intensity projection images of the appropriate channel were used.  To determine 
Tau puncta size or the fluorescence intensity of puncta, images were analyzed using the 
‘background subtracted’ function followed by ‘3D object counter’ function using a 
threshold of 2000.  The threshold value was determined manually and then applied to all 
images, tau fluorescence detected was at least 5X above background.  The object maps 
containing the coordinates of detected objects were saved and manually verified.  The 
output data was also saved and then compiled for all FOV analyzed.  All figures were 
prepared with GraphPad Prism ® version 6.     
4.4.4.4  PSD-95 puncta analysis 
 Images of at least 10 fields of view were taken for both control and HFA infected 
neurons.  Using ImageJ software (NIH), z-stacks images were split into 4 channels and 
MAX-intensity projection images of the appropriate channel were used.  To determine 
PSD puncta size, images were analyzed using the ‘background subtracted’ function 
followed by ‘3D object counter’ function using a threshold of 1700.  The threshold value 
was determined manually and then applied to all images, this allowed PSD-95 
fluorescence detected to be at least 5X above background.  The object maps containing 
the coordinates of detected objects were saved and manually verified.  The output data 
was also saved and then compiled for all FOV analyzed.  All figures were prepared with 
GraphPad Prism ® version 6.     
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5 CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
5.1  Conclusions 
 The mammalian brain is complex and progress in the field is limited by the 
availability of tools to probe the underlying molecular basis of synaptic communication 
and dysfunction.  The cell culture models used throughout this dissertation have both 
advantages and disadvantages.  Heterologous expression systems offer the most 
simplistic system to investigate and modulate synaptic communication.  Dissociated 
primary hippocampal neuron culture allows for investigation and modulation of synaptic 
communication in a simplified system compared to intact brain slice cultures whereas 
slice cultures are a simplified system compared to animal models.  Data generated from 
any of these model systems need to be validated against knowledge generated from 
human brain tissue to ensure global conclusions are representative of synaptic 
communication and dysfunction in the human brain.  
 In this dissertation, I have investigated neuronal communication using novel 
molecules to photocontrol receptors at the synapse, and identified HDAC6 as an 
underlying molecular factor in Alzheimer’s disease (AD) tau pathology and synaptic 
dysfunction.  This research has used techniques in chemical neurobiology, and 
molecular and cellular biology including patch-clamp electrophysiology, immunoblotting, 
and confocal microscopy.  By employing these techniques I have answered questions 
about the function of inhibitory receptor subtypes at synapses, and the role of HDAC6 in 
AD in both heterologous expression systems and primary hippocampal neurons.  This 
research has given insight on the underlying molecular mechanisms of learning and 
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memory by deciphering the role of receptor subtypes in synaptic communication, and 
changes that indicate early synaptic dysfunction in AD.   
 I have described how we have successfully developed a series of LiGABAAR that 
enable light-controlled inhibitory neurotransmission of subtype specific GABA receptors.  
Specifically, we developed α1- and α5-LiGABAARs.  These LiGABAARs enabled 
spatiotemporal precision control of ion channels at the synapse thus allowing us to 
investigate the underlying mechanisms of subtype-specific neural inhibition.  The PTLs 
we developed enabled a method for photocontrolling engineered GABAA receptors that 
was fast, reversible photoregulation, and subtype-specific.  Our experiments revealed 
that tethered muscimol acts as an antagonist to engineered GABAA receptors when 
irradiated with 500 nm light.  This method enabled photoregulation of endogenous 
mIPSCs from dissociated hippocampal neurons expressing LiGABAAR.  Further, this 
method also enabled the photocontrol of action potential firing of intact brain slices.   
 I have used an in vitro heterologous cell culture system to investigate the 
outcome of the overexpression of HDAC6 on tau and protein levels in HEK-tau cells.  
The data from this study suggest that an increase in HDAC6 expression leads to 
increased pathological tau accumulation and may be the result of decreased PP1 levels 
in cells overexpressing HDAC6.  Further, the expression of catalytically inactive HDAC6 
in HEK-tau cells did not prevent the accumulation of increased pathological tau or the 
decrease in PP1 levels.  This data suggests that HDAC6 is a underlying molecular factor 
altering both tau and PP1 protein levels, which may contribute to AD progression.  I also 
verified that HEK-tau cells overexpressing HDAC6 with a catalytically inactive second 
deacetylase domain were in fact catalytically inactive by using a known substrate 
acetylated tubulin as a reporter of cytosolic functional HDAC6.  As expected, HDAC6 
with catalytically inactive second deacetylase domain were unable to deacetylate tubulin.  
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Additionally, this study revealed that the expression of tau does not inhibit the 
deacetylase function of cells overexpressing catalytically active HDAC6.    
 Studies using dissociated primary hippocampal neurons were used to further 
investigate the potential underlying molecular role of HDAC6 in altering key proteins 
involved in AD progression.  For this project, I designed and developed recombinant 
HDAC6 adenovirus for efficient and reproducible HDAC6 gene delivery in neurons.  This 
method resulted in the development of a primary hippocampal neuron cell culture model 
to study hallmarks of AD progression.  The results presented in this dissertation reveal 
increased expression of HDAC6 in dissociated primary hippocampal neurons as an 
underlying molecular factor that contributes to the pathological missorting of 
phosphorylated tau to the soma of affected neurons, reduction of tau puncta, and 
reduction in PSD-95 puncta.  These changes suggest that increased HDAC6 in neurons 
leads to changes in the molecular organization of dendritic spines that suggest HDAC6 
is involved in regulating changes in excitatory neurotransmission and LTD.  The results 
from these experiments suggest dissociated primary hippocampal neurons 
overexpressing HDAC6 can be used as a tissue culture model system to study changes 
correlate with human AD progression and pathology. 
5.2  Future Directions 
 Using the PTL approach, we developed a series of LiGABAARs.  This technology 
enables investigation into the roles that receptor subtypes play in mediating and altering 
synaptic neurotransmission.  Additional studies with these LiGABAARs provide a method 
for precise, reversible photocontrol of sub-type specific receptors to investigate their 
distribution, and examine their functional role in leaning and memory.  By exerting 
photoswitchable control on engineered receptor subtypes in brain slices, we can 
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investigate the role specific subtypes of GABAA receptors in intact brain tissue have in 
preventing epilepsy.  Further, the PTLs we developed can be employed to exert 
photocontrol on future engineered GABAA receptor subtypes of interest.  Additionally, 
‘knock-in’ mice expressing LiGABAARs in place of endogenous subunits could be used 
to study genetically engineered receptors in the absence of wild-type background.  The 
photocontrol of GABA receptor study presented in this dissertation begins to address 
how receptor subtypes contribute to inhibitory synaptic neurotransmission.  The 
suggested future studies would enable further investigation into the role of receptor 
subtypes have in synaptic communication.  This knowledge would further the current 
understanding of the molecular basis of learning and memory.   
 Alzheimer’s disease is a complex, multifactoral, slow progressing disease with no 
cure and little understanding of the underlying molecular basis leading to the 
pathological hallmarks of AD and synaptic dysfunction.  By using a cell culture model, I 
was able to investigate the neuropathological role of HDAC6 and underlying molecular 
contributions that HDAC6 overexpression appears to have in AD tau pathology and 
synaptic dysfunction.  The main advantages of this system are a single gene is altered 
enabling fast, efficient and reproducible pathological hallmarks representative of 
changes in post-mortem AD brains and animal models.  Further studies that investigate 
early synaptic changes such as decreases in excitatory receptors (AMPA and NMDA) 
are possible using dissociated hippocampal neurons overexpressing HDAC6.  Future 
studies using this system can investigate early changes that lead to defects in protein 
degradation and the subsequent accumulation of aggregated proteins.  Additionally, this 
system can potentially be used for a high-throughput drug screen to determine if 
targeting HDAC6 reverses or slows the progression of AD tau pathology and synaptic 
dysfunction.  Alternatively, this system can potentially be used for a high-throughput drug 
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screens to determine if targeting kinases upregulated in AD will reverse or slows the 
progression of AD tau pathology and synaptic dysfunction.  The investigation and 
identification of increased HDAC6 expression as having an underlying neuropathological 
role in AD tau pathology and synaptic dysfunction presented in this dissertation begins to 
investigate early changes in AD that potentially could be targeted to prevent disease 
progression.  The suggested future studies would enable further investigation of early 
changes in AD that may be the result of increased protein levels of HDAC6.  
Investigation of early synaptic changes that contribute to memory and cognitive 
impairment will greatly advancing our understanding of AD progression.   
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